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ABSTRACT 
Folate, homocysteine, and methyl group metabolism mutually function to provide methyl 
groups for numerous biosynthetic- and modification-type reactions necessary for optimal 
health.  Methyl groups from these pathways are utilized in the production of important 
compounds such as nucleic acids, protein, and phospholipids.  Thus it is vital to understand 
the factors that both disrupt and maintain their delicate balance to prevent disease.  
Disruption of these metabolic pathways is associated with several pathologies including 
carcinogenesis, birth defects, and vascular disease.  Moreover, the disruption of these 
metabolic pathways may be a link between chronic disease and complications of that disease.  
Both nutritional and hormonal factors have been shown to modulate these interrelated 
metabolic pathways, commonly altering enzymes involved.   
Diabetes mellitus is estimated to affect approximately 21 million Americans, constituting 
nearly seven percent of the population.  Roughly one-third of this group is unaware that they 
even have diabetes, which is a major cause of morbidity and mortality in this country.  Both 
type 1 and type 2 diabetes, characterized by elevated blood glucose concentrations, lack of or 
insensitivity to insulin, and elevated counter-regulatory hormones to insulin (i.e. glucagon 
and glucocorticoids), have been shown to disrupt folate, homocysteine and methyl group 
metabolism.   
Homocysteine pools, the non-protein forming amino acid synthesized and catabolized by 
these pathways, were also disrupted in diabetics.  Hypohomocysteinemia is commonly 
reported in diabetics without renal complications; however as renal function deteriorates in 
chronic diabetes, hyperhomocysteinemia results.  Furthermore, hyperhomocysteinemia is 
considered an independent risk factor for vascular disease.  It is estimated that heart disease 
and stroke account for 65 percent of deaths in diabetics.  Glycine N-methyltransferase 
(GNMT), the enzyme responsible for controlling methyl group supply and utilization, is also 
disrupted in diabetes, leading to depletion of essential methyl groups.  Activity of this 
enzyme is allosterically regulated by the folate coenzyme, 5-methyltetrahydofolate.   
Vitamin D status has been implicated in diabetic pathogenesis.  In particular, vitamin D 
deficiency has been shown to increase the risk of developing type 1 diabetes and 
supplementation may reduce this risk.  Further, vitamin D deficiency has been associated 
xiii 
 
with impaired insulin secretion and glucose intolerance, but ameliorated by repletion.  As a 
result, this research was aimed at determining if supplemental folate, supplemental vitamin 
D, and insulin repletion could prevent perturbations in homocysteine and methyl group 
metabolism induced by a type 1 diabetic state.  
Insulin administration restored enzyme activity, protein abundance, and homocysteine 
concentrations in diabetic rats.  Indicating perturbations in folate, homocysteine and methyl 
group metabolism do result from a diabetic state and are not the result of streptozotocin 
toxicity.  GNMT, perturbed by a diabetic state, was attenuated in diets containing adequate or 
supplemental folate, likely due to posttranslational modification.  Although these results 
would suggest that adequate folate status has a positive effect under diabetic conditions, 
supplemental folate did not confer any added benefit at the level tested.  Further, betaine 
homocysteine S-methyltransferase (BHMT), the folate-independent remethylation enzyme, 
and GNMT mRNA were induced in diabetic animals indicating modification in a diabetic 
state is possibly at the level of transcription.  Vitamin D supplementation restored 
homocysteine pools disrupted in a diabetic state potentially as a result of increased 
homocysteine production.  This research indicates folate, vitamin D, and insulin may be 
involved in modulating homocysteine and methyl group metabolism in a diabetic state.  
Ultimately it will be critical in future work to more clearly determine and evaluate the factors 
that both regulate and alleviate diabetes-perturbed homocysteine and methyl group 
metabolism for optimal health and prevention of complications associated with diabetes.   
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CHAPTER 1: GENERAL INTRODUCTION 
Thesis Organization 
The contents of this thesis are organized into several chapters.  Chapter 1 is an 
introduction giving the reader an idea of the research questions the author focused on.  
Chapter 2 is broad review of the literature, including information that is pertinent to the 
author’s research in folate, homocysteine, and methyl group metabolism.  Chapter 3 
examines the role of insulin in modulating methyl group metabolism altered by a diabetic 
state.  Modified portions of this chapter were published in the Journal of Nutrition and the 
Federation of American Societies for Experimental Biology Journal.  Chapter 4 contains 
research that was aimed at determining the role of supplemental folate in diabetes-perturbed 
homocysteine and methyl group metabolism.  This chapter was modified from a paper 
published in the American Journal of Physiology-Endocrinology and Metabolism and an 
abstract published in the Federation of American Societies for Experimental Biology Journal.  
Chapter 5 describes a study that was conducted to determine the role of vitamin D in 
homocysteine metabolism, disrupted by diabetes.  A small modified portion of this chapter 
was also published in the Federation of American Societies for Experimental Biology 
Journal.  General conclusions and ideas for future research are incorporated into chapter 6 
including a list of the literature cited throughout the entire document. 
Description of the Research Questions 
The interrelated folate, methyl group, and homocysteine pathways function to carry and 
activate one-carbon units in the synthesis and modification of essential biological 
compounds.  Specifically, these mechanisms are vital in the production of nucleic acids, 
proteins, and phospholipids.  Therefore interruption of these pathways can result in a number 
of diseases including cancer, vascular disease, and birth defects. 
A number of factors have been identified as having the ability to alter folate, methyl 
group, and homocysteine metabolism.  A diabetic state has been identified as one of these 
factors and the focus of this research.  Type 1 and type 2 diabetes, characterized by elevated 
blood glucose, lack of or insensitivity to insulin, and elevated counter-regulatory hormones to 
insulin (i.e. glucagon and glucocorticoids), have been shown to disrupt folate, homocysteine, 
and methyl group metabolism.  Specifically, homocysteine pools, the non-protein forming 
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amino acid synthesized and catabolized by these pathways, are also disrupted in diabetics 
depending on renal function.  Hypohomocysteinemia is commonly reported in diabetics 
without renal complications; however as renal function deteriorates in chronic diabetes 
elevated homocysteine concentrations result.  The enzyme responsible for controlling methyl 
group supply, glycine N-methyltransferase (GNMT), is also disrupted in diabetes leading to 
depletion of essential methyl groups.  GNMT activity is allosterically regulated by the folate 
coenzyme, 5-methyltetrahydofolate.   
Several studies have also reported that compounds capable of simulating a gluconeogenic 
state, including glucagon and glucocorticoids, also have the ability to modify homocysteine 
and methyl group metabolism.  Rats treated with glucagon exhibited elevated activities of 
GNMT and the enzyme that initiates homocysteine catabolism cystathionine β-synthase 
(CBS).  Decreased homocysteine concentrations have also been reported indicating increased 
flux through the transsulfuration pathway.  Administration of the glucocorticoid 
dexamethasone has been shown to induce and activate GNMT in cell culture and animal 
models, as well.  Studies conducted in both streptozotocin-induced diabetic rats and type 2 
diabetic rat models, have also revealed similar modifications in one-carbon metabolism.   
Further, vitamin D status has been implicated in diabetic pathogenesis.  Vitamin D 
deficiency has been shown to increase the risk of developing type 1 diabetes in infants and 
mice models of type 1 diabetes; while supplementation may reduce this risk.  Vitamin D 
deficiency has been associated with impaired insulin secretion and glucose intolerance, but 
ameliorated by repletion.  As a result, the work described in this document was aimed at 
determining if supplemental folate, supplemental vitamin D, and insulin repletion could 
prevent perturbations in homocysteine and methyl group metabolism induced by type 1 
diabetes.  
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CHAPTER 2: A REVIEW OF THE LITERATURE  
Folate Metabolism 
Structure and Function of Folate Compounds  
Structure 
Folate, a generic term for a family of essential water soluble B-vitamins, functions 
primarily to accept and donate one-carbon units in vital metabolic pathways throughout the 
body (16, 158).  This family of vitamins, also known by the chemical name pteroylglutamic 
acid, contains both natural and synthetic forms all of which are similar in structure.  The 
basic structure of folate moieties consists of a pteridine ring, p-aminobenzoic acid, and one or 
more glutamic acid residues linked by γ-carboxyl peptide bonds (Figure 2.1A).  Folate forms 
differ by altering the structure in three locations: modifying the reduction state of the 
pteridine ring, adding one-carbon units at the N5 and/or N10 binding sites (Figure 2.1B), or 
varying the number of glutamic acid residues attached.  Naturally occurring folate is typically 
polyglutamated containing between three and seven glutamyl residues and exists most 
commonly as 5-methyltetrahydrofolate (5-CH3THF) and 10-formyltetrahydrofolate (10-
CHO-THF).  The synthetic form of folate, folic acid used in supplements and fortified foods, 
is monoglutamated (284).    
Figure 2.1A. Basic structure of folate molecules (modified from (284)). 
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Function 
The donation of one-carbon units is essential in the production of nucleic acids (DNA and 
RNA), proteins, as well as in the metabolism of amino acids.  These one-carbon units exist at 
various oxidation levels, as seen in figure 2.1B, and the reactions they are involved in are 
collectively known as folate-dependent one-carbon metabolism (289).  The reduced folate 
derivative, tetrahydrofolate (THF), accepts one-carbon units at the oxidation level of formate 
from histidine degradation, or at the oxidation level of formaldehyde from the 3-carbon of 
serine (248).  However, one-carbon units can also be derived from glycine, dimethylglycine 
(DMG), and N-methylglycine (sarcosine) (284).  Specifically folate, in the form of 10-CHO-
THF, is needed to donate carbon 2 and 8 in the purine component of DNA (Figure 2.2).  The 
folate derivative 5,10-methylenetetrahydrofolate (5,10-CH2THF) is involved in the 
biosynthesis of deoxythymidine monophosphate, from deoxyuridine monophosphate, a 
pyrimidine building block of DNA (241, 248, 289).  Aside from the role of folate in the 
biosynthesis of nucleic acids, one-carbon units as CH3 provided by folate are used in over 
fifty methyltransferase-catalyzed reactions (56, 284) (Figure 2.3).  
Folate Utilization  
Digestion and Absorption 
Mammals are unable to synthesize folates de novo, making it necessary to attain folate 
Figure 2.1B. Folate derivatives (modified from (284)). 
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compounds through consumption (247).  The polyglutamated chain of naturally occurring 
folates must be removed before the vitamin is absorbed.  Excess glutamate residues are 
hydrolyzed by the enzyme γ-glutamyl hydrolase in brush border mucosal cells of the 
proximal small intestine, and in turn this monoglutamated form is absorbed (181).  Typically 
if the folate compound is not already in the form of 5-CH3THF, it will be converted to this 
form and transported through the intestinal mucosa cell (239).  The monoglutamated 
synthetic form of folate is readily absorbed, primarily in the jejunum. 
Transport and Storage 
Following absorption, folate passes through the mucosal cell and is taken up by the liver 
via portal circulation (247).  In the liver, folate remains in the form 5-CH3-THF or is 
otherwise converted to 10-CHO-THF and transported to peripheral tissue (181).  The 
transport of folate into cells can be accomplished by one of three mechanisms: (i) 
unidirectional transport by membrane-bound folate-binding proteins/receptors, (ii) 
bidirectional internalization by carrier-mediated reduced folate carriers, (iii) or by passive 
Figure 2.2. The role folate in purine and pyrimidine biosynthesis (from (241)). 
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diffusion (252, 265).  Once folate enters the cell the enzyme methionine synthase (MS) 
converts 5-CH3THF to THF the favored substrate of the enzyme, folylpolyglutamate 
synthase.  The activity of this enzyme, necessary to retain folate within the cell, results in the 
polyglutamylation of THF and is present in both the mitochondria and cytoplasm (158). 
Polyglutamylated folate is compartmentalized between the cytoplasm and the 
mitochondria (58).  Most folate in the cell is protein-bound and usually remains in their 
respective compartment; however the products that result from folate compounds are easily 
transferred between the cytoplasm and mitochondria (154).  At any time cellular 
concentrations of free folate are negligible due to tight-binding proteins, which also limits 
intracellular folate accumulation when saturated (172).  The body typically stores between 20 
and 70 mg of folate (100, 263), half of which is found in the liver in the form of 5-CH3THF 
(105, 106). 
Figure 2.3.  Folate and one-carbon metabolism (from Scott and Weir 1998) 
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Degradation and Excretion 
Protein-bound folates are stable compared to free-folate, which is often depleted in the 
cell due to its instability.  There are three mechanisms that are thought to cause the turnover 
of folates, specifically unbound folate: exit of folate molecules from lack of 
polyglutamylation, folate polyglutamates are hydrolyzed to monoglutamates by γ-
glutamylhydrolase and exit the cell, or folate catabolism (265).  A majority of folate 
excretion is in feces via bile due to enterohepatic circulation most of which is reabsorbed in 
the intestine.  However, a small portion of excreted folate can be found in urine following 
glomerular filtration and reabsorption of some of the folate (105).  Degradation of folate 
generates pteridines and acetaminobenzoylglutamate.  
Dietary Requirements 
Sources of Folate 
Currently recommendations for folate intake are focused on reducing the risk of chronic 
disease, which means maintaining optimal one-carbon metabolism (31).  Folates are present 
in most natural foods; fruits and vegetables being the richest sources.  Specifically, spinach, 
brussel sprouts, potatoes, oranges, beans, and liver, are excellent sources of folate (15, 284).   
However, these natural forms of folate are particularly susceptible to oxidative damage, and 
it is estimated that 50-95% of the folate is destroyed by cooking excessively (105).  There are 
also several states in the body that can result in altered folate status and increased catabolism 
and in turn increases folate requirement such as pregnancy, oral contraceptive or 
anticonvulsant use, cancer, or chronic alcohol consumption (265).  It is because of this 
potential for folate deficiency and the risk of congenital defects as well as chronic disease 
associated with deficiency that the U.S. Food and Drug Administration made it mandatory 
for enriched grain products to include folic acid (2).   This fortification has led to a decline in 
the prevalence of folate deficiency-related pathologies specifically neural tube defects (113). 
Recommended Intake 
Folate dietary requirements are expressed as recommended dietary allowances (RDA) 
which is derived from the estimated average requirement (EAR) as well as adjusting to meet 
the requirements for approximately 98% of the population.  The EAR is defined as the 
amount needed to meet 50% of the population (16).  Given that synthetic folate is much more 
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readily available than dietary folate, dietary reference intakes (DRIs) for folate are expressed 
as dietary folate equivalents (DFE).  One DFE is equivalent to 1 μg of food folate, 0.6 μg of 
synthetic folate from fortified food or a supplement with food, or 0.5 μg of a supplement on 
an empty stomach (1).    
RDAs vary depending on age and physiological state.  Males and females older than 14 
years of age are recommended to take in 400 μg DFE per day.  The RDA declines for 
children less than 14 years old to between 65 and 80 μg DFE per day in infants up to 12 
months old.  Folate requirements increase in the case of pregnancy and lactation at 600 and 
500 μg DFE per day, respectively (Table 2.1).  This elevated requirement is due to the 
increased need for folate in cell division and increased catabolism of folate during pregnancy, 
as well as the loss of folate in daily lactation following pregnancy (15).  There are also upper 
limits (UL) specified for each age group, meaning the maximum daily intake without 
inducing adverse effects.  In children up to 8 years old the UL is 300-400 μg DFE per day 
and 600-800 μg DFE per day in males and females up to the age of 18 years old.  The UL for 
adults above 19 years old increases to 1,000 μg DFE per day in both males and females 
regardless of pregnancy and lactation (1). 
Methyl Group Metabolism 
Functions and Components of the Metabolic Pathway 
Transmethylation 
Methyl group metabolism functions in activating methyl groups required for numerous 
methylation reactions necessary for normal growth and development.  Methyl group 
metabolism begins with the set of reactions collectively called transmethylation which 
relies on a supply of the essential sulfur-containing amino acid, methionine (78).  Methionine 
is converted to its activated form, S-adenosylmethionine (SAM) following adenylation.  This 
reaction is catalyzed by the enzyme methionine adenosyltransferase (MAT) at the expense of 
ATP (39, 52, 153).  At this point SAM, the primary methyl donor in most mammals can 
donate activated methyl groups to many methylation reactions in the modification and 
synthesis of essential molecules, resulting in S-adenosylhomocysteine (SAH) (169, 191).  
The formation of creatine from guanidinoacetate by guanidinoacetate methyltransferase 
(GAMT) constitutes a major use of methyl groups (194, 260).  However, it has been  
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Table 2.1 
Folate dietary reference intakes1 
Group  Adequate intake (μg of DFE/d) 
Recommended 
dietary allowance 
(μg of DFE/d) 
infants    
0-6 months  65  
7-12 months  80  
children and adolescents2   
1-3 years   150 
4-8 years   200 
9-13 years   300 
4-18 years   400 
adults2    
≥ 19 years   400 
pregnant women   
all ages   600 
lactating women   
all ages   500 
1 modified from Bailey and Gregory 1999 
2 male and female 
 
suggested that phosphatidylethanolamine N-methyltranferase (PEMT) is the primary 
consumer of methyl groups from SAM in the synthesis of phosphatidylcholine (PC) from 
phosphatidylethanolamine (PE), thus being the primary contributor to homocysteine 
production (126, 256).  PEMT accounts for 20-40% of hepatic PC synthesis (267), but can 
increase to compensate for PC production as seen in the CTP:phosphocholine 
cytidylyltransferase-α knockout mouse (126).  These animals are incapable of synthesizing 
PC through the CDP-choline pathway, the primary pathway for PC production.  PC is 
necessary for phospholipids, lipoproteins, and bile, as well as intracellular communication 
(312).  Most SAM-dependent transmethylation reactions are inhibited by SAH, therefore it 
essential to regulate the SAM to SAH ratio as well as remove SAH to preserve methyl groups 
(41). 
The folate-binding protein, glycine N-methyltransferase (GNMT), is believed to function 
in regulating the availability of SAM (60, 310).  GNMT is found in the liver, pancreas, and 
kidney, and comprises approximately 1 to 3 % of all soluble hepatic cytosolic protein (135, 
205).  GNMT was found to be most abundant in the periportal region of the liver, the 
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proximal convoluted tubules of the kidney, and the exocrine tissue of the pancreas (310).  
This methyltransferase converts SAM to SAH, utilizing glycine and forming sarcosine, 
which currently has no known metabolic role (103, 135).  GNMT optimizes the SAM:SAH 
ratio, which is an indicator of transmethylation potential, given SAH is a potent inhibitor of 
most other SAM-dependent methyltransferases (291, 310).  This regulatory role has been 
supported by the GNMT knockout mouse model.  Hepatic GNMT activity and expression 
were completely eliminated in homozygous animals and the SAM:SAH ratio increased by 
over 100-fold (162).  In further support of the regulatory role of GNMT, activity and 
expression of the enzyme were induced in the brain of PEMT knockout mice (318).  The 
activities of all other methyltransferases measured in this study were decreased and low 
levels of GNMT were expressed in the wild type mouse.  GNMT was proposed to dispose of 
methyl groups that were not utilized by the major methyl group consumer, PEMT (318).      
Epigenetic modification of DNA by methylation also requires methyl groups from SAM.  
DNA methylation is a critical tool in regulating tissue-specific gene expression and 
ultimately genome function (222).  DNA methylation alters DNA protein interactions leading 
to either an increase or decrease in gene transcription (130).  The reaction is catalyzed by a 
family of SAM-dependent DNA methyltransferases (DNMTs) (156), which transfer a methyl 
group to cytosine in CpG dinucleotides.  CpG islands are usually found in gene promoter 
regions, thus methylation often results in regulation of DNA expression, typically repression 
(130).  Aberrant DNA methylation is associated with a number of pathologies.  Preneoplastic 
and tumor DNA is characterized by global hypomethylation, regional hypermethylation, and 
increased activity of DNMTs (20, 129, 151).  Development of atherosclerotic lesions has also 
been associated with changes in DNA methylation (73, 110). 
Transmethylation results in the production of homocysteine following the removal of 
adenosine from SAH.  This exclusive metabolic pathway is catalyzed by S-
adenosylhomocysteine hydrolase (SAHH) (40).  This reaction is reversible favoring SAH 
production, and sways in the opposite direction if adenosine and homocysteine can be 
efficiently removed (40, 68, 217) (Figure 2.4). 
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Remethylation 
Two pathways exist that function to metabolize homocysteine: remethylation, recycling 
methyl groups in formation of methionine, or catabolism through transsulfuration forming 
cystathionine (76, 153).  Homocysteine can be remethylated through both folate-dependent 
and folate-independent mechanisms, both pathways contributing equally to the formation of 
methionine (85).   
 
In hepatic tissue and possibly kidney, betaine derived from the oxidation of choline, 
serves as a source of methyl groups in the remethylation of homocysteine via the enzyme 
betaine homocysteine S-methyltransferase (BHMT) (81).  This folate-independent route 
results in methionine and DMG (266).  BHMT appears to provide a regulatory in 
homocysteine homoeostasis, which will be discussed later in this chapter.  However it is 
interesting to note that BHMT was induced in the CTP:phosphocholine cytidylyltransferase-
α knockout mouse.  This model exhibits a 20-40% increase in homocysteine concentrations 
because it compensates for PC production via increased PEMT activity (126).  Moreover, 
Figure 2.4. Folate, methyl group, and homocysteine metabolism 
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administration of a BHMT inhibitor in mice resulted in homocysteine concentrations that 
were elevated 7-fold (57).   
Alternatively, remethylation occurs with the donation of a methyl group by 5-CH3THF 
through the enzymatic action of MS, a vitamin B12-dependent enzyme (85).  Upon donation 
of a methyl group in the remethylation of homocysteine, 5-CH3THF is reduced to 
tetrahydrofolate (THF) (289).  At this point THF can either be reversibly converted to 10-
CHO-THF and donate its one-carbon units in the formation of purines, or combine with 
serine to form 5,10-CH2THF and glycine.  This reaction is reversible catalyzed by the 
enzymatic activity of serine hydroxymethyltransferase (SHMT), which is dependent on 
vitamin B6 as a coenzyme (235).  One-carbon units from 5,10-CH2THF, can then be donated 
to deoxyuridine monophosphate (dUMP) in formation of the DNA precursor thymidylate via 
the catalytic activity of thymidylate synthase (TS, Figure 2.4) (241).   
The folate compound 5,10-CH2THF, is also used in the synthesis of 5-CH3THF, which is 
irreversibly catalyzed by the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR), a 
riboflavin-dependent enzyme.  At any given time the concentration of free folate compounds 
in the cell is insignificant leading to a struggle for folate compounds between folate binding 
proteins, such as MTHFR and TS (235, 264, 265).  The enzyme SHMT, a B6-depedent 
enzyme, provides a regulatory mechanism for distribution of one-carbon units between 
thymidylate and methionine synthesis that when in excess favors thymidylate.  This favoring 
is accomplished by binding and sequestering 5-CH3THF which in turn prevents the 
remethylation of methionine (107). 
Transsulfuration 
Catabolism of the sulfur-containing amino acid homocysteine occurs through a group of 
reactions known as transsulfuration.  The major enzymes involved in this pathway, 
cystathionine β-synthase (CBS) and γ-cystathionase, are vitamin B6-dependent.  The first 
committed step, converting homocysteine to cystathionine is catalyzed by CBS which utilizes 
serine in a condensation reaction (146, 150).  Finally, cystathionine is converted to the amino 
acid cysteine as well as other useful metabolites: glutathione, taurine, and pyruvate (262).  
The enzyme γ-cystathionase initiates this final step of the transsulfuration pathway (260).  
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Transsulfuration does not occur ubiquitously, with some cells lacking part or the entire 
pathway (81). 
Regulation of Methyl Group Metabolism  
Allosteric Regulation 
In order to make certain there is an adequate supply of methyl groups for SAM-
dependent transmethylation reactions a number of regulatory mechanisms exist.  The enzyme 
GNMT is subject to allosteric regulation based on the supply of methyl groups, in the form of 
SAM, to optimize the SAM to SAH ratio (205).  In the state of excess methyl groups through 
the diet or the folate-dependent one-carbon pool excess SAM binds to MTHFR, inhibiting 
enzyme activity (127) (Figure 2.5).  This inhibition reduces the synthesis of 5-CH3THF and 
in turn alleviates the allosteric inhibition 5-CH3THF exerts upon GNMT resulting in the 
disposal of excess methyl groups.  Conversely, in the state of methyl group deficiency, 
reduced circulating SAM concentrations results in increased activity of MTHFR, elevating 
concentrations of 5-CH3THF.  Further, 5-CH3THF allosterically inhibits GNMT thereby 
providing methyl groups for SAM-dependent transmethylation reactions (290).   
In addition to regulating methyl group supply through the enzymes MTHFR and GNMT, 
there are a few other points of control.  Specifically, SAM is a positive allosteric regulator of 
CBS, the enzyme that commits homocysteine to the transsulfuration pathway (82).  Excess 
circulating SAM concentrations will activate CBS resulting in the normalization of methyl 
group supply by increasing catabolism.  Secondly, excess dietary protein ensuing elevated 
SAM concentrations will restrict remethylation enzyme BHMT, again to bring methyl group 
supply to an optimal state (83).  However if methionine is restricted, BHMT gene expression 
is enhanced, conserving methyl groups (212). 
Hormonal Regulation 
Specific hormones have been identified as having the ability to modulate methyl group 
metabolism.  Counter-regulatory hormones to insulin (i.e. glucagon and glucocortiocoids) 
have been shown to modulate key enzymes in methyl group metabolism.  In rat hepatoma 
cells, CBS protein abundance as well as CBS mRNA levels were increased following 
treatment with the synthetic glucocorticoid, triamcinolone.  This effect occurred by 
stimulating gene expression at the transcriptional level, and the stimulatory effect was 
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prevented by insulin treatment (219).  Moreover, treatment with the glucocorticoid 
dexamethasone has shown to induce GNMT activity and protein abundance in rats and rat 
hepatoma cells (230).  Jacobs et al. reported that a state of hyperglucagonemia in rats 
induced activity of CBS, γ-cystathionase, and increased CBS mRNA levels (124).  The study 
also revealed increased concentrations of SAM and SAH, which are allosteric activators of 
CBS, indicating an increase flux through the transsulfuration pathway (124).  The level and 
synthesis rate of BHMT mRNA increased in vitro following triamcinolone treatment and 
decreased with insulin treatment (220).  An earlier study also found that both tramcinolone 
and dexamethasone were capable of inducing MAT activity, protein level, and mRNA 
abundance (94).  Both insulin and actinomycin D prevented this induction indicating 
transcriptional regulation.  Interestingly both the human and rat gene for MAT reportedly 
contain glucocorticoid response elements within the promoter region (12, 316).   
Growth hormone may also affect methyl group metabolism, namely GNMT expression.  
GNMT expression was induced in hypophysecomized rats, but prevented by restoring growth 
hormone levels with daily treatments (9).  Similarly, in Ames dwarf mice which are 
characterized by growth hormone deficiency and an extended lifespan, GNMT activity and 
mRNA abundance were increased as well as MAT, BHMT, SAHH mRNA abundance.  
These animals also exhibit decreased hepatic SAM, increased SAH, and an overall increase 
in the flux of methionine through transsulfuration (35, 281, 282). 
Thyroid hormone status has also been indicated in regulating folate and methyl group 
metabolism.  MTHFR activity has been reportedly increased in hyperthyroidism and reduced 
in hypothyroidism, whereas the opposite was reported for MS activity (196).  Accordingly, 
GNMT activity would be expected to decrease in hyperthyroidism due to the increased 
synthesis of 5-CH3THF and subsequent allosteric inhibition (86).  A study by Tanghe et al. 
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(269) supported this expectation when GNMT activity induced by retinoic acid was 
prevented by triiodothyronine treatment.  Hypothyroidism has been correlated with 
hyperhomocysteinemia in humans (188) and significantly reduced with thyroxine therapy 
(207).  Conversely, hypothyroidism resulted in reduced homocysteine levels in the rat which 
were reversed by thyroid replacement (125). 
Dietary Requirements 
A sufficient supply of methyl groups through the diet, from choline and/or methionine, or 
as a result of the folate-dependent one-carbon pool is necessary for growth and development 
(84).  Currently, only estimates exist for methionine requirements based on nitrogen balance 
studies, which tend to be grouped with the other sulfur-containing amino acid, cysteine.  The 
estimates for methionine/cysteine requirements in mg/kg/day are classified by age as follows: 
3-4 months, 158; 2-5 years, 27; 10-12 years, 22; greater than 12 years, 13 (177).  It is 
definitely necessary to fulfill protein requirements, however excessive methionine can be 
toxic (22).  The incorporation of choline into a low-protein diet at methyl loads at the same 
Figure 2.5. Regulation of methyl group metabolism 
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level or greater than methionine seems to reduce the adverse effects seen with methionine 
(44).  Conversely, there is an adequate intake and UL stated for choline in the current DRIs.  
Adequate intake is given in μg/day and classified by age as follows: 0-12 months, 125-150; 
1-8 years, 200-250; 9-13 years, 375; males greater than 14 years, 550; females 14-18 years, 
400; females greater than 18 years, 425.  A slightly elevated choline recommendation exists 
for pregnant or lactating women at 450 and 500 μg/day, respectively; because large amounts 
are lost across the placenta and to breast milk (1, 311, 313). 
Disruptions in Folate, Homocysteine, and Methyl Group Metabolism and Associated 
Pathologies 
Folate and methyl groups are directly or indirectly involved in cell function, division, and 
differentiation, thus necessary for essential biological processes.  Therefore insufficient 
supply of folate, methyl groups, or related cofactors (e.g. vitamin B6 and B12) can result in a 
multitude of pathologies as a result of disruptions in methyl group metabolism.  In addition to 
nutrient deficiencies, treatment with retinoid compounds has been shown to perturb methyl 
group metabolism.  Lastly, individuals that possess genetic polymorphisms in key enzymes 
involved in these interrelated pathways may cause alterations and susceptibility to associated 
pathologies. 
Neural Tube Defects 
Folate and methyl group metabolism are critical components in fetal development given 
that one-carbon units are needed in the synthesis of DNA, protein, and phospholipids (52).  
Neural tube defects (NTDs) are characterized by malformation of the brain and/or spinal cord 
in the developing embryo, instigating incomplete central nervous system development (284).  
NTDs are one of the most common birth defects occurring in 1 in 1000 births in the United 
States (3, 61). 
The most common manifestations of NTDs are as congenital disorders, spina bifida and 
anencephaly, accounting for 50 and 40% of cases, respectively (242).  Spina bifida is 
distinguished by incomplete closure of the spinal cord (posterior end of the neural tube) 
causing physical disabilities in the child.  Conversely, anencephaly results in incomplete 
closure of the skull (anterior end of the neural tube) and is incompatible with life (98).  The 
etiology of NTDs is continually evolving but not yet clearly understood, with over 90% of 
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NTD cases occurring from unknown causes (284).  Identified origins of NTDs have been 
classified as both genetic and environmental with nutritional deficiency, specifically folate, 
being one of them (158-160).  
Folate status has long been examined for its role in NTDs, with earlier studies reporting 
associations between fetal malformations and folate deficiency (109).  Further interactions 
between NTDs and folate were found in a study that reported low folate stores in women 
with pregnancies affected by NTDs, in turn suggesting periconceptional folate 
supplementation might protect against NTDs (253).  Elucidating the specific mechanism by 
which folate supplementation prevents NTDs is ongoing; however data currently exists 
supporting the beneficial role of folate supplementation in reducing the occurrence of NTDs.  
In particular, it was shown that folic acid treatment alone was just as effective in preventing 
NTDs as a multivitamin with folate (5).  Moreover, a study involving 4,000 women reported 
6 cases of NTDs in women receiving a placebo multi-mineral, as compared to no incidences 
of NTDs in the other group of women given a multivitamin containing folic acid (64).  
Recent reports suggest an inverse relationship between methionine intake (251) and vitamin 
B12 status (140, 236), on the prevalence of NTDs.  Periconceptional folic acid 
supplementation has also been shown to reduce the occurrence of non-NTD birth defects 
such as cleft lips, cleft palates, urinary tract, and cardiovascular congenital abnormalities, as 
well as limb deficiencies (63).  In response to the building evidence of the effectiveness of 
folic acid in the prevention of NTDs, the Center for Disease Control recommended any 
woman of child-bearing age consume at least 400 μg of folic acid per day (6).   
Hyperhomocysteinemia 
Clearance of the non-protein-forming amino acid, homocysteine is dependent on 
remethylation and transsulfuration pathways and is possibly regulated nutritionally (244).  
SAM seems to be a key regulator in homocysteine metabolism since SAM allosterically 
inhibits MTHFR and BHMT and activates CBS.  Folate as well vitamins B6 and B12 are also 
key factors in homocysteine metabolism.  Deficiency in any of these nutrients can result in 
the disruption of homocysteine metabolism, and in turn hyperhomocysteinemia (99). 
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Homocysteine and Vascular Disease 
Hyperhomocysteinemia is positively associated with vascular diseases and has been 
recently added to the list of commonly known risk factors for cardiovascular disease (CVD) 
(152, 245, 246).  However the theory that homocysteine leads to vascular disease was 
proposed long ago when arterial lesions were discovered in children with inborn errors in 
methionine metabolism leading to severe hyperhomocysteinemia (> 100µM) (179, 193).  
Severe hyperhomocysteinemia can result from inborn errors in enzymes necessary for 
clearance of homocysteine, specifically CBS, MTHFR, and MS (55, 244).  Normal plasma 
homocysteine values range from 5-15 µmol/L; whereas ~10 µmol/L is typical in men and 8 
µmol/L in women (31, 257).  An elevation in plasma homocysteine concentrations by as little 
as 1 μmol/L is associated with a 10% increase in the risk of CVD (24).  A meta-analysis 
found that a 25 percent elevation in plasma homocysteine (~3 µmol/L) was associated with a 
10 percent increase risk for developing cardiovascular disease and a 20 percent greater risk of 
stroke (4).  A prospective study found a 27 percent elevated risk of venous thromboembolism 
with a 5 µmol/L increase in plasma homocysteine (71).  Folate deficiency has also been 
linked to elevated plasma homocysteine, with a 9.8-fold increase reported in folate-deficient 
rats as compared to folate-replete controls (185).  A reduction in plasma homocysteine 
concentrations were also evident following administration of folic acid promoting 
remethylation (33, 171, 210, 300).  Therefore it is estimated that increasing folate intake by 
200 μg per day will result in a reduction in homocysteine by 4 μmol/L (31, 285).  
Research is ongoing as to whether homocysteine actually imposes atherogenic effects or 
if it just an indicator of another mechanism (279).  Many studies do support the hypothesis 
that homocysteine is directly involved in vascular disease by causing degeneration of the 
vascular endothelium (158).  Particularly, a study using cultured endothelial cells has 
demonstrated cytotoxic effects following homocysteine treatment (294).  In addition an in 
vivo study revealed the rapid formation of plaques following injection of homocysteine 
thiolactone (180).   
Studies in apolipoprotein E (apoE) and CBS knockout mice have revealed additional 
insight into the role of homocysteine in vascular disease.  ApoE is involved in the removal of 
lipoproteins from the plasma via low density lipoprotein receptors.  ApoE-null mice are 
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severely hypercholesterolemic and develop spontaneous aortic atherosclerotic lesions (214, 
317).  The deletion of the CBS gene creates a model of hyperhomocysteinemia (297).  
Hyperhomocysteinemia has been shown to enhance the formation of lesions leading to 
arterial injury in apoE knockout mice (112).  A study using double knockout mice led to 
aortic lesions regardless of dietary manipulation.  Moreover uptake of modified low density 
lipoproteins by macrophages was increased with elevated homocysteine concentrations 
(295).  Monocyte-derived macrophages and smooth muscle cells that accumulate low-density 
lipoproteins are called foam cells and have been shown to contribute to atherosclerotic 
lesions (104).  Homocysteine has also been shown to increase foam cells and oxidized low-
density lipoprotein content, as well as lead to the accumulation of cholesterol and hydrogen 
peroxide in cultured monocytes (128).  Superoxide dismutase, the free radical scavenger 
enzyme, was also reduced by homocysteine treatment and it was suggested that this effect 
was mediated by methylation.  Oxidative radicals have also been implied as contributors to 
endothelial dysfunction in animals (47, 66, 67, 75, 280, 298).  Studies indicated that elevated 
homocysteine levels results in endothelial cell dysfunction in humans (306) as well as 
vascular smooth muscle cell proliferation (166).  Additional mechanisms indicate 
homocysteine may induce vascular disease by causing platelet function abnormalities; 
however the exact mechanism is yet to be revealed.  
Homocysteine and Neural Tube Defects 
Elevated homocysteine is consistently associated with NTDs which again may be as a 
result of inborn errors in the enzymes (MTHFR and MS) involved in remethylation of 
homocysteine (190, 283).  Further an association has been identified between NTD births and 
increased cellular folate depletion.  This was thought to be a result of impaired folate 
remethylation to THF the main intracellular form of folate (161).  This further identifies the 
need to promote periconceptional vitamin supplementation, specifically folate.  
Cancer 
As explained previously, folate is directly and indirectly involved in the modification and 
synthesis of DNA.  Therefore, folate deficiency has been identified as a factor contributing to 
cancer development and enhancement (170).  Mechanisms for this relationship have been 
proposed but not yet clearly defined (16).  One hypothesis of this relationship is in the 
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donation of one-carbon units from 5,10-CH2THF in the synthesis of the DNA precursor 
thymidylate.  Inadequate folate can lead to misincorporation of uracil into DNA due to lack 
of thymidylate.  This misincorporation can lead to stress of the DNA repair mechanism and 
in turn cause DNA strand breaks and chromosome instability.  However misincorporation of 
uracil and subsequent DNA damage seems to be reduced by folate supplementation (25). 
Another proposed mechanism for this relationship between folate and cancer is the role 
of folate in DNA methylation.  DNA methylation has shown to regulate gene expression, 
with lack of methylation typically leading to gene expression, and increased methylation 
resulting in gene suppression (289).  In addition to methyl groups being provided by protein 
in the diet, folate indirectly plays a role in methylation of DNA by donating a methyl group 
to homocysteine in the generation of SAM.  Therefore, it has been observed that rats fed a 
diet lacking folate, methionine, choline, and vitamin B12, display decreased SAM 
concentrations and hepatic DNA methylation (293).  Global DNA hypomethylation has 
shown to precede cancer development, specifically due to hypomethylation of proto-
oncogenes which increases transcription of associated mRNAs (72). 
An additional hypothesis for the role of folate in cancer is in cytotoxic natural killer cells.  
Natural killer cells provide important immune protection against tumor cells (274).  It was 
proposed that in folate deficiency, these cells have reduced ability to destroy cancerous cells 
(170).  Further research suggests that natural killer cell-mediated cytotoxicity is dependent on 
the state of folate deficiency with severe folate deficiency in rats resulting in the reduced 
ability for cytotoxicity.  However moderate folate deficiency, associated with increased risk 
of some cancers, did not affect cytotoxicity capabilities of natural killer cells (139). 
Accumulating evidence suggests that folate may play a role in development and 
progression of many cancers including: colorectum, lungs, pancreas, esophagus, stomach, 
cervix, breast, and leukemia (136).  The most evidence indicating a relationship between 
folate and cancer development has been documented in colorectal cancer (138, 218).    
Several retrospective studies have suggested a decreased risk of colorectal neoplasms in 
subjects with the highest folate intake; whereas folate deficiency increases the risk of 
colorectal cancer (18, 95).  However folate may have a dual relationship in colorectal 
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carcinogenesis.  Folate deficiency may prevent the progression of established colorectal 
neoplasms, but promote neoplastic formation in normal mucosa (137).  
Megaloblastic Anemia 
Disturbed DNA synthesis as a result of folate and/or B12 deficiency can result in the 
megaloblastic anemia.  This form of anemia manifests in large, immature, abnormal, red 
blood cell precursors in the bone marrow and peripheral blood (133).  The role folate and 
vitamin B12 play in this pathology is in the pathway converting 5-CH3THF to THF through 
the activity of MS (233).  In the case that there is vitamin B12 deficiency, MS activity is 
reduced essentially trapping methyl groups in the form 5-CH3THF.  This “methyl trap” 
decreases the availability of folate coenzymes for purine and pyrimidine biosynthesis, which 
are needed for red blood cell division and differentiation (248).   
This somewhat pseudo folate deficiency that occurs can result in a reduction of SAM and 
in turn methyl groups for transmethylation reactions including myelin basic protein.  A 
decrease in methyl groups for synthesis of myelin basic protein can cause demyelination and 
in turn a state of neuropathy (239).  Therefore, it is crucial that individuals suffering from 
megaloblastic anemia not only supplement folate, but vitamin B12 to prevent associated 
neuropathy.  However, steps should be taken to discover the root of the problem because 
supplementing folate can mask vitamin B12 deficiency and exacerbate associated 
neurological problems (30). 
Neurological/Neuropsychiatric Disorders 
Neurological disorders associated with folate and/or B12 deficiency are not quite as well 
understood as the hematological disorders. Vitamin B12 and folate deficiencies have been 
associated with neurological and neuropsychiatric disorders (29).  A hypothesis for the role 
of these nutrients is again through the reaction catalyzed by MS.  MS, which utilizes both 
vitamin B12 and folate, in the formation of methionine and in turn SAM.  SAM provides 
methyl groups in the synthesis of proteins, phospholipids and neurotransmitters such as 
serotonin, norepinephrine, and dopamine.  Specifically reduced serotonin levels and activity 
have been reported in the brain of folate-deficient rats and humans (28, 119).  It is interesting 
to note that 5-CH3THF is transported across the blood brain barrier, and the concentration in 
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the cerebrospinal fluid is three times greater than in serum (30).  This further indicates the 
importance of the MS-catalyzed pathway.   
Several studies have reported a high incidence of folate deficiency accompanying 
depression (43, 189).  Studies have also been conducted to determine the efficacy of folate 
and SAM supplementation in these affective disorders, whereas supplementation seemingly 
promotes antidepressant activity (89, 97).  However it is not clear if folate deficiency actually 
plays a role in the development of depressive illnesses or if it is secondary to poor appetite.   
Recent studies have also linked the rise in homocysteine, resulting from folate deficiency 
and reduced enzyme activity, to two major neurological disorders: Alzheimer’s disease and 
Parkinson’s disease (178).  Typically serum homocysteine levels are elevated in folate- or 
vitamin B12-deficient patients (11).  There are several suspected mechanisms for the role of 
folate and homocysteine in neuronal damage.  One of these mechanisms is folate deficiency 
is thought to induce DNA damage by reducing homocysteine remethylation to SAM for 
transmethylation reactions (246).  Another possible mechanism is the accumulation of SAH.  
Elevated homocysteine creates a favorable condition for the hydrolysis of homocysteine to 
SAH by SAHH.  SAH accumulation will inhibit SAM-dependent transmethylation reactions, 
and in turn induce DNA damage and cell apoptosis (148).  In addition, it has been shown that 
neurons cultured with homocysteine deplete their ATP reserves in attempts to repair 
damaged DNA.  ATP depletion is thought to be a key factor in the degeneration of neurons in 
Alzheimer’s and Parkinson’s diseases (148).   
Genetic Profile 
Genetic polymorphisms are among the factors that can perturb folate, homocysteine, and 
methyl group metabolism resulting in associated pathologies.  These genetic differences are 
in key enzymes in one-carbon metabolism and typically result in reduced activity.  Several of 
these polymorphisms have been identified as well as the possible side effects of their 
existence. 
MTHFR Polymorphism 
The enzyme MTHFR catalyzes the irreversible conversion of 5,10-CH2THF to 5-
CH3THF, which donates its methyl group in the remethylation of homocysteine.  The most 
common mutation of this enzyme is autosomal recessive, occurring at base pair 677, and 
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resulting in a C→T substitution (C677T) causing valine to substitute for alanine in the 
enzyme (90).  The frequency of this mutation varies depending on race and ethnic 
background, but it is estimated to occur at rate of 12% in Caucasian and Asian populations 
homozygous for the trait, and up to 50% for those who are heterozygous for the trait (33).   
Individuals that are homozygous for this mutation exhibit reduced activity and stability of 
MTHFR.  Studies indicate that persons with the homozygous C677T mutation have reduced 
plasma folate concentrations and elevated plasma homocysteine concentrations (33).  Modest 
elevations in homocysteine is an independent risk factor for vascular disease and NTDs; 
however studies are conflicting as to whether the homozygous C677T mutation is itself a risk 
factor in vascular disease and NTDs (17).  The relationship between cancer and the 
homozygous C677T mutation seems to be dependent on folate status.  A decreased risk for 
colorectal cancer was found in men with normal plasma folate concentrations and the 
MTHFR mutation by increasing the availability of one-carbon units for nucleotide synthesis.  
Conversely, the men with low folate status seemed to counteract the protective effect of the 
mutation (165). 
MS Polymorphism 
The enzyme MS has also been identified in the list of mutations associated with one-
carbon metabolism.  The most common MS polymorphism is located at base pair 2756 
causing an A→G (A2756G) substitution and resulting in glycine replacing aspartic acid in 
the functional enzyme (48).  It is not yet clear whether this mutation changes activity or 
abundance of the enzyme; however most research indicates there is no association between 
this mutation and homocysteine concentrations (120, 141).  Most studies also indicate that 
there is no association between the homozygous mutation for MS and the risk for vascular 
disease (164, 187, 276).  Although a study by Kerk et al. (141) did find that subjects 
homozygous for the MS mutation exhibited a four-fold increase in the risk of coronary heart 
disease as compared to individuals with the wild-type or heterozygous genotypes. 
CBS enzyme deficiency 
The transsulfuration pathway beginning, with the CBS activity, plays a crucial part in the 
removal of homocysteine when the supply of methyl groups is in excess (85).  Therefore, a 
deficiency in CBS activity results in hyperhomocysteinemia, homocystinuria, methionine in 
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the plasma and urine, decreased cystathionine and cysteine levels, in addition to the possible 
manifestation of a number of pathologies (145, 244).  Specifically, osteoporosis, scoliosis, 
arteriosclerosis, thromboembolism, convulsions, and psychiatric disturbances are some 
pathologies that can develop from this enzyme deficiency (142), and as many as 50% of 
those who go untreated, develop mental retardation (308).  The exact mechanism by which 
CBS enzyme deficiency is associated with diseases is not yet known.   
CBS enzyme deficiency is an autosomal recessive trait and the most common inborn 
error of methionine metabolism occurring in approximately 1 in 200,000 individuals 
worldwide (246).  Greater than 60 mutations have been identified in the CBS gene (144).  
The most severe mutations occur at base pair 833 resulting in a T→C (T833C) substitution 
and at base pair 919 resulting in a G→A substitution (G919A).  These mutations are fairly 
rare affecting less than 1% of the general population (143).  The most common mutation is 
caused by a 68 base pair insertion between nucleotides 844 and 845 (844ins68).  This 
mutation occurs in the heterozygous form in approximately 12 % of the U.S. population 
(275). 
CBS is a vitamin B6-dependent enzyme, therefore some patients with CBS deficiency 
respond to vitamin B6 supplementation resulting in lower homocysteine concentrations.  It is 
estimated that approximately 50% of those with CBS enzyme deficiency respond to high 
doses of vitamin B6, evident by lowered homocysteine concentrations (195).  However, many 
individuals do not respond to vitamin B6 supplementation and therefore must rely on a 
methionine-restricted diet.  Vitamins B12, B6, and folate may further reduce homocysteine 
concentration in these resistant individuals (301).  Betaine supplementation has also been 
tested in mouse models of CBS deficiency and humans and has been found to consistently 
lower plasma homocysteine concentrations.  The only concern is the elevated methionine 
levels that result, however most patients seem to remain below 1500 μmol/L, a level that has 
not been associated with adverse effects (238, 301, 302). 
GNMT polymorphism 
Reports of mutations in the gene that codes for GNMT have been reported in humans 
(192), and has since been mimicked in a GNMT knockout mouse model (162).  The 
mutations found in siblings with severe enzyme deficiency were two single nucleotide 
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substitutions: (i) T→C at nucleotide 1481, and (ii) C→A at nucleotide 3715.  The transitions 
ultimately changed leucine to proline and histidine to aspargine, respectively, in the 
translated protein (13, 163).  These patients exhibited severe hypermethioninemia and normal 
plasma sarcosine levels despite a drastic elevation in plasma SAM levels, as well as elevated 
liver transaminases and hepatomegaly. 
An additional study examining GNMT in human liver cancer progression identified six 
novel polymorphisms (277), since GNMT is typically diminished in hepatoma cells (14, 49, 
102).  Further examination of the 1289 C→T (C1289T) polymorphism (TT genotype), which 
was associated with cancer risk (277), found higher homocysteine concentrations in women 
following folate restriction as compared to CT or CC genotypes (21).  This effect was 
exacerbated by the presence of the MTHFR C677T mutation. 
Retinoids 
Factors both nutritionally and hormonally have been identified as having the ability to 
alter methyl group metabolism by targeting key enzymes involved.  Specifically the vitamin 
A derivatives, all-trans-retinoic acid (RA), and 13-cis-retinoic acid (CRA) are among these 
factors.  More importantly these alterations may affect those who utilize these derivatives 
therapeutically.  CRA (Isotretinoin/Accutane®) is used in dermatology and taken orally to 
treat cystic acne that is unresponsive to topical treatment; whereas RA (Vesanoid®) is used 
in oncology to treat promyelocytic leukemia (206, 213).  
Retinoid administration has been shown to affect one-carbon metabolism by increasing 
methionine catabolism as well as inducing hypomethylation of DNA by activating GNMT in 
rats (77, 229, 234).  An additional study also found elevated homocysteine concentrations in 
humans treated with isotretinoin, linking this finding to either CBS inhibition or liver 
dysfunction (237).  CRA and RA have been shown to induce GNMT activity and protein 
abundance in vivo (182, 208, 231) as well as induction of GNMT by RA in vitro (230).  
Induction of GNMT results in a loss of methyl groups for subsequent SAM-dependent 
transmethylation reactions.  This effect seems to be dose-dependent with as little as 5 
μmol/kg body weight and a single dose causing significant induction and a maximal effect at 
30 μmol/kg body weight and four days of treatment (208).  Activation of GNMT by retinoids 
also exhibited tissue and gender specificity.  McMullen et al. reported male rats were more 
26 
 
sensitive to retinoid-mediated activation of GNMT than female rats (182).  Retinoid 
administration resulted in elevated hepatic GNMT protein and abundance, but did not affect 
renal or pancreatic GNMT (182). 
 RA is known to induce a gluconeogenic state which in turn alters methyl group 
metabolism through the induction of key gluconeogenic enzymes including 
phosphoenolpyruvate carboxykinase, the rate-limiting step of gluconeogenesis (209, 250).  
Interestingly, GNMT is located primarily in gluconeogenic tissues implying a possible role in 
hormonal regulation.  These modifications of GNMT activity by RA are thought to occur 
transcriptionally, however there is currently no report of a retinoic acid response element on 
the promoter region of GNMT (209).  Phosphorylation of GNMT has been shown to 
modulate activity of the enzyme.  Wagner et al. found in vitro that phosphorylation, by 
cAMP-dependent protein kinase, of GNMT resulted in a 2-fold increase in the activity of the 
enzyme; however if 5-CH3THF was first bound to GNMT, phosphorylation was inhibited as 
well as enzyme activity (292).  
Diabetes Mellitus 
Diabetes-Perturbed Folate, Homocysteine, and Methyl Group Metabolism 
A diabetic state is commonly characterized by chronic hyperglycemia and defects in the 
action and/or secretion of insulin.  Diabetes leads to disturbances in macronutrient 
metabolism and ultimately damage and dysfunction of tissues especially in the eyes, kidneys, 
and vascular system (23).  A diabetic state has also been indicated in directly altering 
enzymes involved in folate, homocysteine, and methyl group metabolism.  In a study by Xue 
and Snoswell, a 65-fold induction in GNMT activity was reported in alloxan-induced 
diabetic sheep (307).  Similarly, in an alloxan-induced diabetic state or a starvation state in 
rats, resulted in a 2-fold induction in GNMT activity (310).  Increased GNMT activity and 
abundance, CBS abundance, and BHMT activity, as well as decreased homocysteine and MS 
activity have also been shown in streptozotocin-induced diabetic rats (198). 
Modifications in homocysteine concentrations are also evident in a diabetic state, but 
appear to be dependent on the status of the kidneys (27, 305).  The kidney is considered the 
main site of homocysteine uptake and metabolism (26), and renal hyperfiltration is 
characteristic of early renal dysfunction in diabetes (272).  If renal function is sufficient, a 
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diabetic condition results in a marked decrease in plasma homocysteine concentrations.  
However, if diabetes is coupled with renal dysfunction, the outcome is elevated plasma 
homocysteine levels (108, 216).  Elevated homocysteine is an independent risk factor for 
vascular disease, and is considered to be the major cause of death in diabetics (223).  In a 
study by Jacobs et al. (123), researchers examined this effect in streptozotocin-induced 
diabetic rats and found plasma homocysteine concentrations were reduced by 40%; however 
treatment with insulin prevented the decrease in homocysteine, indicating insulin may be 
involved in the regulation.  This decline in homocysteine likely manifests through the 
modification of transsulfuration enzymes, cystathionine β-synthase and γ-cystathionase 
(123).  Further, in streptozotocin-induced diabetic rats elevated CBS mRNA abundance was 
prevented by insulin administration (219).  Homocysteine kinetic studies in healthy humans 
revealed increased homocysteine clearance following insulin infusion (271).  Folate-
independent remethylation may also contribute to reduced plasma homocysteine 
concentrations since activity and mRNA of BHMT were elevated in streptozotocin-induced 
diabetic rats (197, 198, 220). 
Similar disruptions in methyl group metabolism have been exhibited in a model of type 2 
diabetes, the leptin-receptor defective (db/db) Zucker diabetic fatty (ZDF) rat.  Total plasma 
homocysteine levels were reduced in these animals at both the pre-diabetic insulin resistant 
stage (5 weeks) and early type 2 diabetes (11 weeks) (299).  Renal hyperfiltration and 
proteinuria have been reported in ZDF rats up to three months of age.  Filtration rate 
typically decreases, to the level reported in normal rats, but proteinuria has been shown to 
increase further by seven months of age (115).  Similarly, lower serum homocysteine 
concentrations have also been reported in non-diabetic insulin-resistant patients (226).  Flux 
studies in type 2 diabetic patients with nephropathy reveal hyperhomocysteinemia regardless 
of insulin stimulation; owing to decreased homocysteine clearance and transsulfuration 
(271). 
Reduced plasma homocysteine concentrations in ZDF rats are likely due to increased 
clearance of homocysteine via increased activity of BHMT, γ-cystathionase, and CBS (299).  
The increased BHMT activity was accompanied by a depletion of hepatic betaine 
concentrations in the rats as well as a reduction in the export of homocysteine from 
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hepatocytes isolated from the ZDF rats (299).  Due to increased folate-independent 
remethylation, diabetics may have an increased betaine requirement.  In support of this 
hypothesis, betaine supplementation was found to reduce homocysteine concentrations in 
healthy human subjects as well as MTHFR-deficient (258) and CBS-deficient mice (238).  
Hepatic SAM and SAH were also increased in ZDF rats, but an overall decrease in the ratio 
of SAM to SAH was reported.  Decreased lymphocytic MTHFR activity, increased 
erythrocyte SAH, and decreased erythrocyte SAM and the ratio of SAM:SAH have been 
shown with the progression of nephropathy in diabetic patients (216).  An additional study in 
type 2 diabetic patients found increased plasma homocysteine, SAM, and SAH, but a 
decrease in the plasma SAM:SAH ratio with the progression of renal insufficiency (108).  
Decreased SAM and the SAM:SAH ratio may indicate a mechanism for 
hyperhomocysteinemia in diabetic nephropathy since SAM stimulates CBS activity, the rate-
limiting step of homocysteine catabolism (79, 261). 
Vitamin D and Diabetic Pathogenesis 
Vitamin D is obtained through limited sources in the diet such as fish, eggs, meat, and 
fortified foods and endogenously synthesized in the skin from a cholesterol derivative 
following sun exposure (173).  The major circulating form of vitamin D, 25-hydroxyvitmain 
D3 (i.e. 25(OH)D3, cholecalciferol, or vitamin D3), requires two hydroxylation reactions to 
form the active metabolite 1,25-dihydroxyvitamin D3 (i.e. 1,25(OH)2D3 or calcitriol).  The 
hydroxylation reactions are catalyzed by enzymes in the P450 family, the first reaction 
occurring in the liver by 25-hydroxylase (173).  The second hydroxylation reaction occurs 
most commonly in the kidney by 1α-hydroxylase but is also expressed in dendritic, 
macrophage, colon, placenta, breast, prostate, and pancreas cells (167).  Vitamin D 
metabolites circulate attached to a chaperone protein called vitamin D binding protein.  At 
the site of interest 1,25(OH)2D3 functions metabolically by binding to the nuclear vitamin D 
receptor, altering the transcription of genes regulated by 1,25(OH)2D3 (173).  Vitamin D 
classically functions in the metabolism and maintenance of calcium and bone. 
Since receptors for the metabolically active form of vitamin D have been indentified in 
tissues unrelated to calcium and bone metabolism, particularly the β-cells of the pancreas, the 
classical role of vitamin D is expanding.  A growing collection of evidence indicates a 
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relationship between vitamin D and diabetes.  In non-obese diabetes-prone (NOD) mice, 
treatment with 1,25 (OH)2D3, prevented the onset of type 1 diabetes (175, 315) and has also 
been shown to improve streptozotocin-induced diabetes (70, 174).  This effect was not 
reported in vitamin D receptor knockout mice (174).  Moreover vitamin D deficiency 
seemingly accelerates diabetes onset in NOD mice (96, 315).  It has also been suggested that 
increasing vitamin D intake as early as infancy, may decrease the risk of the child developing 
type 1 diabetes later in life (7, 121, 259).   
In type 2 diabetic humans and animals, vitamin D deficiency has been reported to inhibit 
insulin secretion and impair glucose tolerance (54, 93, 202).  Further, vitamin D repletion 
seems to ameliorate the noted abnormalities in insulin secretion and glucose tolerance (131, 
203).  Glucose concentrations in type 2 diabetic rats were reduced by 40% with vitamin D3 
supplementation (69).  Reduced circulating insulin and elevated blood glucose have been 
reported in mice without a functional vitamin D receptor (314).  Epidemiological evidence 
has also indicated that serum 25-hydroxyvitamin D3 levels in adults are inversely correlated 
with the occurrence of type 2 diabetes, insulin resistance (243), and metabolic syndrome (87, 
167).  However these associations have yet to be confirmed by intervention studies.   
Summary 
Folate, homocysteine, and methyl group metabolism function in concert to mobilize and 
activate one-carbon units, primarily methyl groups, in the biosynthesis and modification of 
essential compounds necessary for optimal health.  Thus, disruption of these critical 
pathways has been associated with a number of pathologies including cancer, vascular 
disease, and birth defects. A number of factors have been indentified as having the ability to 
disrupt folate, homocysteine, and methyl group metabolism.  Specifically, we and others 
have reported that a diabetic state disrupts these metabolic pathways, possibly connecting 
diabetes to complications of the disease.  The research described in the following chapters 
was aimed at preventing disruptions in folate, homocysteine, and methyl group metabolism 
resulting from a diabetic state. 
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CHAPTER 3: MODULATION OF METHYL GROUP BY INSULIN 
TREATMENT IN DIABETIC RATS 
 
Modified from a paper published in the Journal of Nutrition1 and an abstract published in the 
Federation of American Societies for Experimental Biology Journal2 
 
Abstract 
Modifications in methyl group and homocysteine metabolism are associated with a 
number of pathologies including vascular disease, cancer, and neural tube defects.  A diabetic 
state is known to alter both methyl group and homocysteine metabolism depending on renal 
function.  Elevated plasma homocysteine results in a diabetic state with compromised renal 
function, whereas diabetes without renal dysfunction is characterized by 
hypohomocysteinemia.  Glycine N-methyltransferase (GNMT) is a major regulatory protein 
that controls the supply and utilization of methyl groups.  We have shown previously that a 
diabetic state: (i) induces GNMT activity as well as protein and mRNA abundance, and (ii) 
reduces plasma homocysteine pools by stimulating its catabolism and folate-independent 
remethylation.  This study was conducted to determine if insulin plays a direct role in the 
regulation of homocysteine concentrations and GNMT.  Rats were randomly assigned to one 
of three groups: control, streptozotocin (STZ)-induced diabetic (60 mg/kg BW), and insulin-
treated diabetic (1.0 unit, b.i.d.).  After 5 days, the 1.5-fold elevation in GNMT activity and 
hypohomocysteinemia in diabetic rats was completely prevented by insulin treatment. 
Additionally, disruptions in methionine synthase (MS), phosphatidylethanolamine N-
methyltransferase (PEMT), and DNA methylation were also prevented by insulin 
administration.  Similar findings have been reported in a type 2 diabetic model, thus we 
hypothesized that glucose or insulin levels may represent a regulatory signal to modify 
GNMT and homocysteine.  In support of this hypothesis, blood glucose concentrations were 
negatively correlated with total plasma homocysteine (r = -0.49, p = 0.05), and positively 
correlated with GNMT activity (r = 0.80, p = 0.0001).  Future research will focus on 
elucidating the role of glucose or insulin as a signal for regulating homocysteine and methyl 
group metabolism. 
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Introduction 
The primary methyl donor, S-adenosylmethionine (SAM), requires a constant supply of 
methyl groups for numerous transmethylation reactions including the biosynthesis and 
modification of nucleic acids, proteins, and phospholipids (X→X-CH3, Figure 3.1)(176, 
289).  Methionine, provided through the diet or endogenously via homocysteine 
remethylation, is activated by methionine adenosyltransferase (MAT) forming SAM (176, 
194).  SAM donates methyl groups in over 50 known mammalian transmethylation reactions, 
including the synthesis of phospholipids, namely phosphatidylcholine (PC) (289).  PC is 
synthesized from phosphatidylethanolamine (PE) through the activity of PEMT.  PEMT is a 
primary consumer of methyl groups from SAM and thought to be a major contributor to 
homocysteine production (126, 256).   
Epigenetic modification of DNA by methylation also requires methyl groups from SAM.  
DNA methylation is a critical tool in regulating tissue-specific gene expression and 
ultimately genome function (222).  The reaction is catalyzed by a family of SAM-dependent 
DNA methyltransferases (DNMTs) (156), which transfer a methyl group to cytosine in CpG 
dinucleotides.  Aberrant DNA methylation is associated with a number of pathologies, 
including carcinogenesis and atherosclerosis (20, 73, 110, 129, 151). 
Management of methyl group supply is essential and accomplished through the 
enzymatic activity of GNMT.  GNMT is an abundant hepatic cytosolic protein, comprising 
approximately one to three percent of all soluble cytosolic protein (135, 205).  GNMT 
functions in optimizing the SAM:S-adenosylhomocysteine (SAH) ratio using methyl groups 
from SAM to convert glycine to sarcosine and SAH (310).  The SAM:SAH ratio is an 
indicator of transmethylation potential since SAH is a potent inhibitor of most 
transmethylation reactions (40, 135), except GNMT which is only weakly inhibited (268).  
Alternatively, GNMT activity is allosterically regulated by the folate coenzyme 5-
methyltetrahydrofolate (5-CH3THF) in response to methyl group supply (309).  SAM is a 
negative allosteric regulator for 5,10-methylenetetrahydrofolate reductase (MTHFR), the 
enzyme responsible for 5-CH3THF production (127, 149).  Excess methyl groups in the form 
of SAM inhibit MTHFR activity and 5-CH3THF synthesis.  This alleviates the negative 
allosteric regulation of GNMT by 5-CH3THF, and allows disposal of excess methyl groups in 
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the conversion of glycine to sarcosine.  Alternatively, during conditions of methyl groups 
shortage, the negative regulation of MTHFR by SAM is alleviated.  As a result, synthesis of 
5-CH3THF is increased, inhibiting GNMT activity and conserving methyl groups for 
transmethylation reactions (291).  A lack of methyl groups for these essential reactions may 
also result in a number of pathologies including carcinogenesis, neural tube defects, and 
cardiovascular disease (132, 227, 240).  The non-protein forming amino acid homocysteine is 
produced following the hydrolysis of SAH by SAH hydrolase (SAHH)(38, 51).  
Homocysteine is either remethylated to methionine or catabolized through the 
transsulfuration pathway to homocysteine. 
The irreversible catabolism of homocysteine ultimately results in cysteine via the 
transsulfuration pathway.  Transsulfuration is the result of two B6-dependent enzymes.  
Cystathionine β-synthase (CBS) catalyzes the first reaction, the condensation of 
homocysteine with serine, resulting in cystathionine production.  Finally, cysteine is 
produced in a reaction catalyzed by γ-cystathionase (147).  Homocysteine remethylation 
occurs by both folate-dependent and folate-independent mechanisms, which have been found 
to contribute equally to the remethylation of homocysteine (85).  Folate-dependent 
remethylation requires donation of a methyl group from 5-CH3THF.  This reaction is 
catalyzed by the B12-dependent enzyme MS, resulting in methionine and tetrahydrofolate 
(THF) (248).  Betaine, derived from the oxidation of choline, is the methyl group donor in 
folate-independent remethylation.  Betaine-homocysteine S-methyltransferase (BHMT) 
catalyzed this reaction, forming dimethylglycine and methionine (91). 
Several factors have been identified as having the ability to influence homocysteine and 
methyl group metabolism by disrupting the expression of key enzymes involved.  A diabetic 
state, characterized by reduced insulin levels, elevated glucose, and elevated circulating 
counter-regulatory hormones (i.e. glucagon and glucocorticoids) (304), has been indentified 
in the disruption of homocysteine and methyl group metabolism.  Altered homocysteine 
concentrations are commonly reported and have been shown to be inversely correlated with 
kidney function (232, 305).  In both type 1 and 2 diabetes without renal complications 
hypohomocysteinemia has been found in humans and rats (8, 123, 198, 224, 299).  Similar 
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findings have also been reported in animals and cells treated with glucocorticoids and 
glucagon (124, 219, 230). 
Hypohomocysteinemia likely results from increased transsulfuration as evidenced by 
increased CBS activity, protein, and mRNA levels as well as γ-cystathionase activity (198, 
219, 299).  Folate-independent remethylation may also assist in the reduction homocysteine 
via BHMT; its activity and mRNA levels have been reportedly increased in acute diabetes 
(198, 220, 299).  However, as renal function declines in chronic diabetes, homocysteine 
levels rise (53, 118, 216). As previously noted, elevated plasma homocysteine is currently 
considered and independent risk factor for the development of vascular disease (31, 55, 132).   
We have shown a diabetic state induced by streptozotocin (STZ) leads to the disruption of 
these vital pathways.  This disruption is characterized by induction of GNMT and PEMT, a 
reduction in methionine synthase activity, as well as altered homocysteine metabolism (197, 
198).  Typically insulin is administered in a type 1 diabetic state, to control blood glucose 
levels.  Consequently, this research was conducted to determine if insulin (INS) prevents 
STZ-induced diabetic perturbations in methyl group metabolism. 
Materials & Methods 
Chemicals 
 Reagents used in this study were obtained from the following sources: S-adenosyl-L-
[methyl-3H]methionine, PerkinElmer Life Sciences; chemiluminescent Western blotting 
detection reagents, GE Healthcare; streptozotocin, S-adenosyl-L-methionine, and porcine 
insulin, Sigma-Aldrich; goat anti-mouse IgG horseradish peroxidase, Southern 
Biotechnology; HpaII endonuclease and BssHII endonuclease, New England Biolabs Inc.; 
[3H]-dCTP, NEN Life Science Products.  The GNMT antibody was generously provided by 
Dr. Yi-Ming Chen of the National Yang-Ming University, Taipei, Taiwan (155).  All other 
chemicals were of analytical grade. 
Animals 
Male Sprague-Dawley rats (125-149 grams) were kept in individual plastic cages and 
housed in a room with a 12-hour light:dark cycle.  Animals were allowed access to food and 
water ad libitum.  Following a 6 day acclimation period on the control diet (230) each animal 
was randomly assigned to one of three treatment groups: control, STZ-induced diabetic 
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(STZ), or insulin (INS)-treated diabetic (STZ+INS).  At the end of the acclimation period 
animals received a single intraperitoneal injection of STZ (60 mg/kg body weight) or the 
vehicle (10 mM citrate buffer, pH 4.5).  The following day rats were given insulin injections 
(1 unit/200 μL saline), b.i.d., every 12 hours (88), for a period of 5 days or the vehicle alone.  
Animals were anesthetized the next day with a mixture of ketamine:xylazine (90:10 mg/kg 
body weight) and heparinized whole blood was collected by cardiac puncture.  An aliquot 
was removed for the determination of blood glucose concentrations using a commercial kit 
(Sigma-Aldrich).  The remaining whole blood was centrifuged at 5,000 × g for 5 minutes and 
the plasma was removed and stored at -20°C for subsequent determination of homocysteine 
concentrations.   Immediately following blood collection, portions of the liver were removed 
and homogenized in ice-cold phosphate-buffered (10 mM, pH 7.0) sucrose (0.25 M) 
containing 1 mM EDTA, 1 mM sodium azide, and 0.1 mM phenylmethylsulfonyl fluoride.  
Homogenates were centrifuged at 20,000 × g for 30 minutes and an aliquot of the supernatant 
was stored at -70°C for determination of GNMT activity and abundance, and MS activity.  
An additional aliquot was removed and centrifuged at 100,000 × g.  The pellet was collected 
for analysis of PEMT activity by resuspending the pellet in 0.25 M sucrose buffer and storing 
at -70°C.   Additional portions of the liver were collected and snap-frozen in liquid nitrogen 
for methylation analysis and quantification of hepatic SAM and SAH concentrations.  Total 
soluble protein concentration of the cytosolic and microsomal fractions were determined 
using a commercial kit (Coomassie Plus, Pierce) based on the Bradford method (32) and 
bovine serum albumin as the standard.   
GNMT Activity Analysis 
The enzymatic activity of GNMT was determined using the method described by Cook 
and Wagner (59) with minor modifications.  The assay mixture (100 μL) contained 0.2 M 
Tris buffer (pH 9.0), 2 mM glycine, 5 mM dithiothreitol, 1 mM S-adenosyl-L-[methyl-
3H]methionine, and was initiated with 250 μg protein followed by incubation at 25°C for 30 
minutes.  Trichloroacetic acid (10%, w/v) was added to terminate the reaction followed by 
the addition of activated charcoal and centrifugation (14,000 × g) to remove radiolabeled 
SAM.  Aliquots of the supernatants were removed for liquid scintillation counting.   
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Determination of GNMT Abundance 
GNMT protein abundance was quantified using immunoblotting techniques as described 
by Rowling et al. (230).  A 10-20 percent (w/v) gradient SDS-polyacrylamide gel was used 
to quantify the 32-kDa monomer subunit of GNMT.  Following separation, proteins were 
transferred to a nitrocellulose membrane and incubated overnight at 4°C with a 1:5,000 
dilution of the monoclonal GNMT antibody (155).  The membrane was then incubated with 
goat anti-mouse IgG horseradish peroxidase secondary antibody for 1 hour at room 
temperature.  GNMT protein abundance was visualized with chemiluminescence and 
exposed to Kodak X-Omat AR film.  Densitometric analysis was performed using SigmaGel 
software (SPSS).  
Total Plasma Homocysteine Analysis  
 Total plasma homocysteine concentrations were determined using HPLC and 
fluorescence detection (278).  Plasma, derivatized with 10 percent (v/v) tributylphosphine in 
dimethylformamide, was incubated at 4°C for 30 minutes.  The reaction was terminated with 
ice-cold trichloroacetic acid containing 1 mM EDTA.  Following centrifugation at 1,000 × g 
for 5 minutes, supernatants were added to a solution containing 0.125 M borate buffer (pH 
9.5), 1.55 M sodium hydroxide, and 0.1 percent (w/v) 4-fluoro-7-sulfobenzofurazan 
(ammonium salt).  N-acetylcysteine (1 mM) was also added to the plasma samples as an 
internal standard.  Samples were injected onto a μBondapak C18 Radial-Pak column 
(Waters), followed by equilibration in a mobile phase consisting of 4 percent acetonitrile in 
0.1 M monobasic potassium phosphate buffer (pH 2.1).  
Determination of DNA Methylation 
DNA methylation status was assessed by measuring the in vitro incorporation of methyl 
groups into global and CpG island DNA as described by Pogribny et al. (215), with minor 
modifications.  DNA was purified from liver samples (186) using a commercial kit 
(Promega).  The DNA (1.25 μg) was then digested overnight using HpaII endonuclease for 
global DNA and BSHII endonuclease for CpG island digestion (New England Biolabs Inc.).  
The assay mixture consisted of 1.0 μg digested DNA, 1X PCR Buffer II, 1mM magnesium 
chloride, 0.5 U AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA), and 9.3 
μM [3H]-dCTP (NEN Life Science Products, Boston, MA) in a total volume of 40 μL.  
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Following a one hour incubation period at 55°C, samples were applied to DE81 ion exchange 
filter paper, washed with 0.5 M sodium phosphate buffer, dried, and [3H]-dCTP 
incorporation was quantified via liquid scintillation counting.  The extent of [3H]-dCTP 
incorporation is directly proportional the number of original unmethylated sites (215). 
MS Activity Analysis 
The activity of MS was determined as previously described by Keating et al. (134).  The 
reaction mixture contained 500 mM sodium phosphate buffer (pH 7.5), 1.3 μM 
cyanocobalamin, 1 M dithiothreitol, 10 mM SAM, 82.4 mM β-mercaptoethanol, 100 mM 
homocysteine, and 15 mM [methyl-14C]-THF (0.17 μCi/μmol).  This mixture was added to 
liver supernatants and incubated for one hour at 37°C.  Ice-cold water was added to terminate 
the reaction and the assay mixture was immediately applied to an AG 1-X8 (chloride form) 
resin column.  Effluent fractions (3 mL deionized water) were collected for subsequent liquid 
scintillation counting.  Homocysteine was prepared fresh daily from a thiolactone derivative. 
PEMT Activity Analysis 
PEMT activity was determined by measuring the incorporation of radiolabeled methyl 
groups from S-adenosyl-L-[methyl-3H]methionine into phospholipids according to the 
method of Duce et al. (74) with modifications.  Briefly, the reaction mixture contained 10 
mM HEPES (pH 7.3), 4 mM dithiothreitol, 5 mM MgCl2, 0.1 mM SAM, 2 μCi S-adenosyl-
L-[methyl-3H]methionine, and 750 μg protein in a final volume of 550 μL.  Exogenous PE 
was not added to the reaction mixture since because it has not been shown to significantly 
increase the reaction rate (34, 111).  The reaction was initiated by adding 750 μg microsomal 
protein and incubated in a 37°C water bath for 10 minutes.  The reaction was terminated by 
pipeting 100 μL of the assay mixture into 2 mL chloroform: methanol: 2 N HCl (6:3:1, 
v:v:v), in duplicate.  The chloroform phase was washed three times with 1 mL 0.5 M KCl in 
50 percent (v/v) methanol, transferred to glass scintillation vials, and allowed to dry at room 
temperature.  The lipid fraction was reconstituted in scintillation fluid and the radioactivity 
was determined by liquid scintillation counting.   
Statistical Analysis  
The mean values of each treatment group were analyzed by a two-way ANOVA test.  
When the variance between means was found to be significant, mean values were compared 
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using Fisher’s least significant difference procedure.  GNMT activity and total homocysteine 
were both compared with the blood glucose levels using the Pearson correlation analysis 
(254).  ANOVA, Fisher’s least significant difference procedure, and Pearson’s correlation 
analysis were performed using SigmaStat software and a significance level of 5 percent. 
Results 
Cumulative weight gain is not affected by insulin treatment in diabetic rats; however 
blood glucose concentrations are restored.  Diabetic rats gained approximately 50 percent 
less weight than control rats (Table 5.1).  Insulin-treated diabetic rats gained approximately 
40 percent more weight than diabetic rats; however, this gain did not reach statistical 
significance (p = 0.07).  STZ was effective at inducing a diabetic state in non-fasted rats 
evident by a 2.9-fold increase in blood glucose concentrations.  Further, insulin treatments 
effectively reduced blood glucose concentrations in non-fasted diabetic rats to 50 percent of 
concentrations exhibited in diabetic rats that received only saline injections. 
GNMT induction in diabetic animals is prevented by insulin treatment, and positively 
correlated with blood glucose concentrations.  Hepatic GNMT activity was elevated 1.6-fold 
in STZ-induced diabetic rats, compared to control rats (Figure 3.2A).  However, insulin 
treatments in diabetic rats restored activity levels to that of control animals, reaching only 70 
percent of activity levels exhibited by diabetic rats.  Similarly, activity levels were reflected 
in abundance of the protein (Figure 3.2B).  GNMT abundance was 1.9-fold greater in STZ-
induced diabetic animals, as compared the control group.  Again, insulin prevented this 
induction in diabetic rats, reaching only 75 percent of abundance levels evident in diabetic 
animals that received only saline.  Moreover, when plotting GNMT activity against blood 
glucose concentrations for each animal, a positive correlation was established (r = 0.80, p = 
0.0001, Figure 3.3). 
Insulin treatment reverses hypohomocysteinemia in diabetic rats, and negatively 
correlates with blood glucose concentrations.  Total plasma homocysteine concentrations 
were reduced 2.3-fold by STZ-induced diabetes, compared to the control group (Figure 3.4).  
Insulin treatments seemed to prevent hypohomocysteinemia in diabetic rats, elevating plasma 
homocysteine levels 2.8-fold over diabetic rats that did not receive insulin.  When total 
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plasma homocysteine concentrations were plotted against blood glucose concentrations for 
each rat, a negative correlation was evident (r = -0.30, p = 0.10, Figure 3.5) 
Both global and CpG island hepatic DNA hypomethylation were restored by insulin 
treatments in diabetic animals.  Hepatic global DNA methylation was reduced 4.7-fold in 
diabetic animals, compared to the control group (Figure 3.6).  Similarly, a diabetic state also 
induced hepatic CpG hypomethylation, where DNA methylation was reduced 1.4-fold as 
compared to control animals.  Insulin treatments returned methylation status to levels 
comparable to that of control animals.  Hypomethylation in insulin-treated diabetic rats 
reached only 24 and 68 percent of the CpG and global hypomethylation status exhibited by 
diabetic rats, respectively.     
Hepatic MS and PEMT activity are altered in diabetic animals but returned in insulin-
treated diabetic rats.  As seen previously, hepatic activity of folate-dependent remethylation 
enzyme MS is dramatically reduced (2.5-fold) by an STZ-induced diabetic state, as compared 
to control animals (Table 3.2).  However, with the addition of insulin injections, MS activity 
increased 2.4-fold to within the activity level of the control group.  Conversely, a diabetic 
state increased hepatic PEMT activity 1.5-fold.  Again, this increase in PEMT activity was 
prevented with insulin injections in diabetic animals, where activity levels reached only 70 
percent of activity levels exhibited by diabetic animals.  Interestingly, PEMT activity was 
also positively correlated with blood glucose concentrations (r = 0.40, p = 0.80, Figure 3.7) 
Discussion 
The disruption of homocysteine and methyl group metabolism has been repeatedly linked 
to numerous pathologies.  It is subsequently vital to maintain normal methyl group 
metabolism and homocysteine homeostasis, as well as identify those factors that may disrupt 
these metabolic pathways for optimal health.  We and others have clearly established that a 
diabetic state disrupts homocysteine and methyl group metabolism.  Specifically a type 1 
diabetic state seemingly results in a functional methyl group deficiency owing to the 
induction of PEMT, GNMT, and reduced MS activity (101, 197, 198).  Type 1 diabetics 
typically maintain blood glucose concentrations with insulin injections.  Insulin treatment has 
reportedly reversed the induction of homocysteine transsulfuration and folate-independent 
remethylation in streptozotocin-induced diabetic rats and cells treated with glucocorticoids 
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(123, 219, 220).  We have also shown in vitro, that pretreatment with insulin prevents 
glucocorticoid-induced GNMT induction (198). GNMT has been established as regulator of 
methyl group supply since it is (i) abundant, (ii) less sensitive to SAH inhibition compared to 
other methyltransferases, (iii) its product sarcosine has no known physiological function, and 
(iv) its activity is inhibited by 5-CH3THF (135, 289, 291, 310).  As a result the present study 
was aimed at determining if insulin could also maintain normal methyl group metabolism, 
namely GNMT, which is otherwise perturbed by STZ-induced diabetes.   
Untreated STZ-treated rats were clearly diabetic in our study as indicated by a 3-fold 
increase in blood glucose concentration as compared to control levels.  Insulin treatments 
effectively returned blood glucose levels to within normal values.  Plasma homocysteine 
levels were significantly reduced in diabetic animals and restored by insulin treatment, as 
previously reported (123).  Hypohomocysteinemia, in diabetic humans and animals with 
normal renal function, typically assessed by creatinine levels, is commonly reported and 
thought to be the result of increased transsulfuration of the amino acid as well as increased 
folate-independent remethylation (123, 198, 220, 224, 299).  However, as kidney function 
deteriorates, homocysteine disposal becomes impaired, consequently homocysteine levels 
rise (271, 305).   
We have expanded on previous knowledge, showing that STZ-induced GNMT and 
PEMT induction and DNA hypomethylation were prevented by insulin treatment, 
conceivably restoring methyl group supply.  PEMT is considered a major consumer of 
methyl groups from SAM, thus a major contributor to homocysteine production (256).  
However elevated PEMT in diabetic rats was not correlated with elevated plasma 
homocysteine levels, likely due to increased transsulfuration and folate-independent 
remethylation in STZ-induced diabetic rats (123, 197, 220).  Moreover, GNMT and PEMT 
activity levels positively correlated and homocysteine concentrations negatively correlated 
with blood glucose concentrations.  This supports a role for insulin or glucose in the 
regulation of these enzymes possibly at the level of transcription.  This speculation can be 
further supported by a lack of response to treatment that was exhibited by a few animals, as 
evident by their blood glucose concentrations, yet removal of these data points did not 
improve the correlation.  It will be critical in future studies to assess mRNA abundance and 
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elucidate a mechanism for the protection provided by insulin.   However we have previously 
reported that GNMT mRNA abundance is upregulated in a diabetic state and further 
actinomycin D, a potent inhibitor of transcription, prevents induction of GNMT by 
glucocorticoids in vitro (197)(Rowling and Schalinske, unpublished data).  Additionally, 
insulin may regulate gene transcription of other additional enzymes involved in 
homocysteine and methyl group metabolism.  More specifically insulin decreased BHMT 
gene transcription rate and in turn mRNA abundance in rat hepatoma cells (220).  Insulin 
also prevented CBS mRNA levels elevated by glucocorticoids and STZ-induced diabetes 
(123, 219).   
In agreement with previous studies (198, 220), hepatic SAM and SAH were significantly 
elevated in STZ-induced diabetic rats (304.1 ± 117.3 versus 24.2 ± 3.3 and 188.3 ± 33.8 
versus 77.6 ± 4.6, respectively) and returned with insulin treatments (18.6 ± 5.1 and 83.0 ± 
8.5, respectively, data not shown).  Hepatic SAM levels are also elevated in a type 2 diabetic 
rat model without renal complications (299) and in the glucagon-treated rat (124).   In 
contrast to Ratnam et al. (220), the SAM:SAH ratio was also elevated in diabetic rats and 
returned to normal levels by insulin administration.  In support of this previous reports 
indicate the SAM:SAH ratio is also elevated in STZ-induced diabetic rats, however the trend 
did not reach significance (p=0.1)(198).  However, the degree of impaired renal function in 
type 2 diabetics has been positively associated with plasma SAH and homocysteine 
concentrations and negatively correlated with the SAM:SAH ratio (108).  Thus our treatment 
period may have been insufficient for elevating SAH and decreasing the SAM:SAH ratio.   
It is plausible that SAM may also serve as a regulator in response to hormones.  
Interestingly elevated MAT activity and mRNA abundance have been reported in 
glucocorticoid-treated rats (94) and a rat model of type 2 diabetes (299).  SAM is considered 
a regulator of methyl group metabolism, as it allosterically activates CBS, committing 
homocysteine to transsulfuration to manage accumulation (82).  Thus elevated SAM in 
diabetic animals may be promoting increased transsulfuration and the characteristic reduction 
in homocysteine levels in diabetic animals and humans with normal renal function.  SAM 
also negatively regulates MTHFR, decreasing production of 5-CH3THF and removing 
inhibition of GNMT.  This may explain both the reduction in folate-independent 
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remethylation via MS and increased GNMT activity in diabetic animals.  Further PEMT 
activity has been reportedly increased following methionine infusion and subsequently 
elevated SAM and the SAM:SAH ratio (286).  The SAM:SAH ratio was not reduced, which 
would have been a likely explanation for DNA hypomethylation since SAH is a potent 
inhibitor of methyltransferases.  However, since PEMT and GNMT activity are elevated and 
methyl groups from the one-carbon pool are reduced, a functional methyl group deficiency 
may exist in diabetic animals; ultimately decreasing methyl groups for DNA methylation.  In 
support of this explanation, hypomethylation was also reported in rats treated with retinoic 
acid, which also induced GNMT (229).  Further, DNA hypomethylation has also been 
reported in folate deficiency (19, 296).   
In summary, we have shown that disruption of methyl group metabolism disrupted by a 
type 1 diabetic state was prevented by insulin.  This provides further insight for insulin or 
glucose as a regulator of homocysteine and methyl group metabolism, and stresses the 
importance of blood glucose control in diabetics.  Importantly similar disturbances have been 
reported in type 2 diabetic rat models (220) and humans with insulin resistance (226).  Thus 
future research needs to be aimed at more closely identifying the protection provided by 
insulin in maintaining these important metabolic pathways. 
Footnotes 
1 Hartz CS3, Nieman KM3, Jacobs RL4, Vance DE4, Schalinske KL3. Hepatic 
phosphatidylethanolamine N-methyltransferase and homocysteine metabolism in diabetic 
rats. J Nutr 136(12): 3005-3009, 2006. 
2 Nieman KM, Schalinske KL. Modulation of methyl group and homocysteine 
metabolism by insulin treatment in diabetic rats. FASEB J 20(4): A607, 2006 (abstr.). 
3 Graduate students and associate professor, Interdepartmental Graduate Program in 
Nutritional Sciences and the Department of Food Science and Human Nutrition, Iowa State 
University. 
4 Research associate and professor, Canadian Institutes of Health, Research Group on the 
Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta, Canada. 
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Tables 
 
 
 
 
 
Table 3.1 
 
Cumulative weight gain and blood glucose concentrations in streptozotocin (STZ)-
induced diabetic rats with or without insulin (INS) treatment1 
 
 Cumulative Weight Gain (g) Blood glucose (mM) 
Control 60 ± 2a 9.0 ± 1.0a 
STZ 29 ± 4b 26.1 ± 1.3b 
STZ+INS 42 ± 9b 13.2 ± 2.8a 
1Values are means ± S.E. (n = 4-6).  Data in each column with distinct letters are 
significantly different (p ≤ 0.05). 
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Table 3.2 
 
Hepatic enzyme activity of methionine synthase (MS) and phosphatidylethanolamine N-
methyltransferase (PEMT) in insulin (INS)-treated diabetic rats induced by streptozotocin 
(STZ)1  
1Values are means ± S.E. (n = 4-6).  Data in each column with different letters are 
significantly different (p ≤ 0.05). 
 MS                    (pmol/min•mg protein) 
PEMT                    
(pmol/min•mg protein) 
Control 56 ± 5a 36 ± 5a 
STZ 22 ± 4b 55 ± 5b 
STZ+INS 52 ± 9b 38 ± 3a 
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Figure Legends 
Figure 3.1 
Folate, homocysteine, and methyl group metabolism.  Methionine provided via the diet or 
endogenously following remethylation of homocysteine is activated, with the addition of 
adenosine, to S-adenosylmethionine (SAM).  This reaction, requiring ATP, is catalyzed by 
the enzyme methionine adenosyltransferase (MAT).  SAM is the primary methyl group 
donor in numerous transmethylation reactions.  The donation of a methyl group by SAM in 
various methylation reactions (X→X-CH3) results in S-adenosylhomocysteine (SAH).  The 
activity of phosphatidylethanolamine N-methyltransferase (PEMT), a major consumer of 
methyl groups from SAM, results in the production of phosphatidylcholine (PC) from 
phosphatidylethanolamine (PE).  Since SAH is a potent inhibitor of most transmethylation 
reactions it is critical to regulate the SAM:SAH ratio, which is accomplished by glycine N-
methyltransferase (GNMT).  This abundant cytosolic protein accomplishes this control by 
utilizing methyl group from SAM in the conversion of glycine to sarcosine.  SAH is 
hydrolyzed to the non-protein forming amino acid homocysteine by SAH hydrolase (SAHH).  
Homocysteine exists at a branch point in these interrelated metabolic pathways.  The amino 
acid can be irreversibly catabolized to cysteine through transsulfuration or remethylated, 
restoring methionine pools.  Homocysteine transsulfuration to cysteine relies on two B6-
dependent enzymes cystathionine β-synthase (CBS) and γ-cystathionase.  Remethylation of 
homocysteine occurs by both folate-independent and folate-dependent pathways.  Betaine, 
formed following the oxidation of choline, provides a methyl group in folate-independent 
remethylation.  Dimethylglycine (DMG) and methionine result from the activity of betaine-
homocysteine S-methyltransferase (BHMT).  Folate-dependent remethylation functions 
through the donation of a methyl group by 5-methyltetrahydrofolate (5-CH3THF).  The B12-
dependent enzyme methionine synthase (MS) catalyzes this reaction forming tetrahydrofolate 
(THF) and methionine.  THF utilizes a carbon from serine generating 5,10-
methylenetetrahydrofolate (5,10-CH2THF), which is irreversibly reduced to 5-CH3THF by 
the B2-dependent enzyme 5,10-CH2THF reductase (MTHFR). 
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Figure 3.2 
Hepatic glycine N-methyltransferase (GNMT) activity and protein levels are restored by 
insulin in streptozotocin (STZ)-induced diabetic and insulin-treated diabetic rats (STZ+INS).  
Rats were acclimated to their diet and surroundings for a 6 day period.  At the end of the 
acclimation period rats received a single intraperitoneal injection of STZ (60 mg/kg body 
weight) or the vehicle 10 mM citrate buffer (pH 4.5).  The following day rats were given INS 
injections (1.0 unit/200 µL saline) or the vehicle twice daily for 5 days.  Liver was collected 
from these animals and GNMT activity and abundance were determined as described under 
“Materials and Methods.” A: Hepatic GNMT activity in diabetic and insulin-treated diabetic 
rats.  Data are expressed as means ± S.E. (n = 4-6), where an asterisk (*) indicates a 
statistically significant difference (p ≤ 0.05).  B:  GNMT abundance was assessed by 
Western blot analysis using a monoclonal antibody.  Data are expressed as means ± S.E. (n = 
4-6) and an asterisk (*) denotes a significant difference (p ≤ 0.05).  Data are displayed as a 
percent of the control group mean in addition to a representative blot. 
Figure 3.3 
Hepatic glycine N-methyltransferase (GNMT) activity positively correlates with blood 
glucose concentrations in diabetic and insulin-treated diabetic rats.  Hepatic GNMT activity 
data was plotted against blood glucose concentration for the same animals as described for 
Figure 3.2 and within the “Materials and Methods” section.  Each treatment group is 
represented by a distinct symbol: control, ●; streptozotocin (STZ)-induced diabetic, ■; 
insulin-treated diabetic (STZ+INS), ♦.  A trend line was drawn which best fit the data and the 
correlation statistics are noted on the graph. 
Figure 3.4 
Insulin restores plasma homocysteine concentrations in diabetic rats.  Plasma was 
collected from the same animals described for Figure 3.2: control, streptozotocin (STZ)-
induced diabetic, and insulin treated diabetic (STZ+INS) rats.  Total homocysteine was 
quantified using HPLC with fluorometric detection as describe in the “Materials and 
Methods” section.  Data are expressed as means ± S.E. (n = 4-6) with and asterisk (*) 
indicating a significant difference (p ≤ 0.05). 
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Figure 3.5  
Total plasma homocysteine negatively correlates with blood glucose concentrations in 
diabetic and insulin-treated diabetic rats.  Plasma homocysteine data was plotted against 
blood glucose concentration for the same animals as described for Figure 3.2 and within the 
“Materials and Methods” section.  Each treatment group is represented by a distinct symbol: 
control, ●; streptozotocin (STZ)-induced diabetic, ■; insulin-treated diabetic (STZ+INS), ♦.  
A trend line was drawn which best fit the data and the correlation statistics are noted on the 
graph.   
Figure 3.6 
Hypomethylation of hepatic global and CpG island DNA is reversed by insulin (INS) 
treatment in streptozotocin (STZ)-induced diabetic rats.  Liver was collected from the same 
animals as described for Figure 3.2 for DNA isolation.  Methylation status was assessed 
using [3H]-dCTP, where incorporation of radiolabeled dCTP is directly proportional to 
unmethylated sites as described in the “Materials and Methods” section.  Data are expressed 
as means ± S.E. and presented as a percent of the respective control group mean.  Bars 
denoted with an asterisk (*) indicate a significant difference (p ≤ 0.05). 
Figure 3.7 
Hepatic phosphatidylethanolamine N-methyltransferase (PEMT) activity positively 
correlates with blood glucose concentrations in diabetic and insulin-treated diabetic rats.  
Hepatic PEMT activity data was plotted against blood glucose concentration for the same 
animals as described for Figure 3.2 and within the “Materials and Methods” section.  Each 
treatment group is represented by a distinct symbol: control, ●; streptozotocin (STZ)-induced 
diabetic, ■; insulin-treated diabetic (STZ+INS), ♦.  A trend line was drawn which best fit the 
data and the correlation statistics are noted on the graph. 
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Figure 3.2A 
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Figure 3.2B 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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CHAPTER 4: FOLATE STATUS MODULATES THE INDUCTION 
OF HEPATIC GLYCINE N-METHYLTRANSFERASE AND 
HOMOCYSTEINE METABOLISM IN DIABETIC RATS1 
 
Modified from a paper published in the American Journal of Physiology-
Endocrinology and Metabolism1 and an abstract published in the Federation of American 
Societies for Experimental Biology Journal2 
 
Abstract 
A diabetic state induces the activity and abundance of glycine N-methyltransferase 
(GNMT), a key protein in the regulation of folate, methyl group, and homocysteine 
metabolism.  Because the folate-dependent one-carbon pool is a source of methyl groups and 
5-methyltetrahydrofolate allosterically inhibits GNMT, the aim of this study was to 
determine if folate status has an impact on the interaction between diabetes and methyl group 
metabolism.  Rats were fed a diet containing deficient (0 ppm), adequate (2 ppm), or 
supplemental folate (8 ppm) for 30 days, after which diabetes was initiated in half of the rats 
by streptozotocin treatment.  The activities of GNMT, phosphatidylethanolamine N-
methyltransferase (PEMT), and betaine homocysteine S-methyltransferase (BHMT) were 
increased approximately 2-fold in diabetic rat liver; folate deficiency resulted in the greatest 
elevation in GNMT activity.  The abundance of GNMT protein and mRNA, as well as 
BHMT mRNA, were also elevated in diabetic rats.  Hyperhomocysteinemia in folate-
deficient rats was attenuated by streptozotocin, likely due in part to increased BHMT 
expression.  These results indicate that a diabetic state profoundly modulates methyl group, 
choline, and homocysteine metabolism, and folate status may play a role in the extent of 
these alterations.  Further, the up-regulation of BHMT and PEMT may indicate an increased 
choline requirement in the diabetic rat.   
Introduction 
The folate-dependent one-carbon pool and methyl group metabolism are interrelated 
pathways critically important in optimal health, as perturbation of these metabolic processes 
is associated with a number of pathologies including cardiovascular disease, cancer 
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development, and birth defects (Figure 4.1) (132, 227, 240).  The primary methyl group 
donor, S-adenosylmethionine (SAM), requires a constant supply of methyl groups from the 
diet and/or the one-carbon pool for numerous transmethylation reactions, such as the 
synthesis of phosphatidylcholine (PC) by the action of the liver-specific enzyme 
phosphatidylethanolamine N-methyltransferase (PEMT) (176).  Therefore, it is essential to 
regulate the supply and utilization of methyl groups to optimize SAM-dependent 
transmethylation reactions, a function that is accomplished by the enzymatic activity of a key 
regulatory protein, glycine N-methyltransferase (GNMT).  GNMT is an abundant protein in 
the liver, comprising approximately 1-3 percent of all hepatic cytosolic protein, and has also 
been identified in renal and pancreatic tissue (205, 310).  GNMT optimizes the SAM/ S-
adenosylhomocysteine (SAH) ratio by catalyzing the conversion of SAM and glycine to SAH 
and sarcosine, respectively (41, 42, 103).  Because SAH is a potent inhibitor of 
methyltransferase activity (135), optimizing the SAM/SAH ratio serves to regulate the 
transmethylation capacity of the cell (289). 
Following SAM-dependent transmethylation and the hydrolysis of SAH by SAH 
hydrolase (SAHH), the resulting homocysteine can be remethylated back to methionine or 
further catabolized through the transsulfuration pathway to cysteine by the initial action of 
cystathionine β-synthase (CBS).  Remethylation occurs through both folate-dependent and 
folate-independent pathways, both contributing equally to methionine regeneration (85).  The 
folate-independent remethylation route utilizes betaine, derived from the oxidation of 
choline, and the enzymatic action of betaine homocysteine S-methyltransferase (BHMT) that 
results in the formation of dimethylglycine and methionine (81).  Alternatively, 
homocysteine can be remethylated through the donation of a methyl group from 5-
methyltetrahydrofolate (5-CH3-THF) via the B12-dependent enzyme methionine synthase 
(MS), resulting in tetrahydrofolate (THF) and methionine.  An inability of the cell to 
remethylate or catabolize homocysteine can result in hyperhomocysteinemia, an independent 
risk factor for cardiovascular disease (55, 132). 
Because of its central role in methyl group and homocysteine metabolism, the regulation 
of GNMT is an important control point.  In a state of excess methyl groups, the resulting 
increase in SAM acts as an allosteric inhibitor of the enzyme 5,10-methylenetetrahydrofolate 
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reductase (MTHFR) (127, 149), decreasing its activity and the subsequent production of 5-
CH3-THF.  This alleviates the negative allosteric regulation 5-CH3-THF imposes on GNMT, 
thereby increasing its activity and disposing of the excess methyl groups.  Conversely, a lack 
of methyl groups results in an increase in MTHFR activity and 5-CH3-THF concentrations, 
thereby inhibiting GNMT and conserving methyl groups for transmethylation reactions 
(291).   
A type 1 diabetic state has been identified as a pathological factor in the modulation of 
methyl group and homocysteine metabolism.  A reduction in circulating concentrations of 
homocysteine as a result of increased catabolism through the transsulfuration pathway, 
namely by the transcriptional regulation of CBS, has been demonstrated in a streptozotocin 
(STZ)-induced diabetic rat model (123, 219).  Recently, we have shown that a diabetic state 
leads to the disruption of hepatic methyl group metabolism, characterized by elevations in 
GNMT activity and abundance, as well as an increase in the folate-independent 
remethylation of homocysteine by BHMT (198).  Similarly, administration of specific 
counter-regulatory hormones to insulin (e.g. dexamethasone and glucagon) have also been 
shown to alter methyl group and homocysteine metabolism both in vivo and in vitro (124, 
230).  Because the folate-dependent one-carbon pool supplies methyl groups for the 
remethylation of homocysteine and SAM-dependent transmethylation reactions, and serves 
as a regulatory mechanism for the control of GNMT activity via allosteric inhibition by 5-
CH3-THF, the aim of this study was to examine how dietary folate status may impact the 
previously reported findings.  We have also extended our earlier studies by examining the 
activity of PEMT, because it is a key enzyme in the SAM-dependent synthesis of PC and 
regulation of homocysteine homeostasis (200, 249). 
Materials and Methods 
Chemicals and Reagents  
Reagents used in the research methods were obtained from the following sources: S-
adenosyl-L-[methyl-3H]methionine, PerkinElmer Life Sciences; chemiluminescent Western 
blotting detection reagents, Amersham Biosciences; streptozotocin and S-adenosyl-L-
methionine, Sigma-Aldrich; goat anti-mouse IgG horseradish peroxidase, Southern 
Biotechnology.  Dr. Yi-Ming Chen of National Yang-Ming University, Taipei Taiwan, 
 58 
 
generously provided the GNMT antibody (155).  All other chemicals were of analytical 
grade.   
Animals 
All experiments involving animals were approved by and conducted in accordance with 
the Iowa State University Laboratory Animal Resources guidelines.  Male Sprague-Dawley 
rats (50-74 grams) were obtained from Harlan Sprague-Dawley (Indianapolis, IN) and 
housed in separate cages with a 12-h light: dark cycle.  Animals were allowed access to food 
and water ad libitum.  Rats were randomly assigned to treatment groups and fed an amino-
acid defined diet (# TD.03333, Harlan Teklad, Madison, WI, Table 4.1) containing either 0 
(folate-deficient, FD), 2 (folate-adequate, F), or 8 ppm folate (folate-supplemented, FS).  
After 30 d, half of the rats in each dietary folate group received a single intraperitoneal 
injection of streptozotocin (STZ, 60 mg/kg body weight) or vehicle (10 mM citrate buffer, 
pH 4.5).  On day 35, non-fasted rats were anesthetized 3-4 hours into the light cycle with a 
single intraperitoneal injection of ketamine:xylazine (90:10 mg/kg body weight) and 
heparinized whole blood was collected by cardiac puncture.  An aliquot was removed for the 
determination of blood glucose concentrations using a commercial kit (Sigma-Aldrich); the 
remaining whole blood sample was centrifuged at 4,000 × g for 6 min and the plasma was 
removed for storage at -20°C for subsequent analysis of homocysteine concentrations.  
Portions of the liver were rapidly removed and homogenized in four volumes of ice-cold 
buffer containing 10 mM sodium phosphate (pH 7.0), 0.25 M sucrose, 1 mM EDTA, 1 mM 
sodium azide, and 0.1 mM phenylmethylsulfonyl fluoride.  Homogenates were centrifuged at 
20,000 × g for 30 minutes and the resulting supernatant was stored at -70°C after the addition 
of β-mercaptoethanol to a final concentration of 1 mM.  These samples were used for the 
determination of enzyme activities (GNMT, BHMT, MS) and abundance (GNMT).  A 
second liver sample was homogenized in 4 volumes of ice-cold sodium acetate buffer (100 
mM, pH 4.9) containing 0.5 percent ascorbate (w/v) and 20 mM 2-mercaptoethanol under a 
steady stream of nitrogen, tightly capped, and stored at –70°C for determination of hepatic 
folate concentrations.  Additional whole liver samples were placed in liquid nitrogen or 
RNAlater™ (Qiagen) and stored at -70°C for subsequent isolation of microsomes (PEMT) or 
mRNA (GNMT, BHMT), respectively.  Total soluble protein concentration of the 
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supernatants was determined using a commercial kit (Coomassie Plus, Pierce) based on the 
Bradford method (32) and bovine serum albumin as a standard.  All enzyme assays were 
linear with respect to protein concentration and incubation time. 
Determination of GNMT Activity and Abundance 
The enzymatic activity of GNMT was measured based on the method of Cook and 
Wagner (60) with slight modifications (230).  The assay was performed in triplicate using 
250 μg protein and a reaction mixture containing the following: 200 mM Tris buffer (pH 
9.0), 2 mM glycine, 5 mM dithiothreitol, and 0.2 mM S-adenosyl-L-[methyl-3H]methionine.  
Abundance of the GNMT protein was determined by immunoblotting methods described 
previously (230) using a 10-20 percent (w/v) gradient SDS-polyacrylamide gel to separate 
the 32-kDa monomer subunit of the protein.  Proteins were transferred to nitrocellulose paper 
and incubated with a 1: 4,000 dilution of the monoclonal GNMT antibody (155) overnight at 
4°C.  The membrane was then incubated with a 1:5,000 dilution of a goat anti-mouse 
horseradish peroxidase secondary antibody for one hour at room temperature.  Proteins were 
detected using chemiluminescence and band density was determined using SigmaGel 
software (SPSS, Chicago, IL).   
Determination of PEMT Activity 
Approximately one gram of frozen liver was homogenized in 4 volumes of ice-cold 10 
mM Tris HCl (pH 7.4) containing 0.25 M sucrose.  The homogenate was centrifuged at 
16,000 × g for 20 minutes at 4°C and 1-2 mL of the resulting supernatant was centrifuged at 
105,000 × g for 60 minutes at 4°C.  The microsomal pellet was resuspended in 400 μL of 
0.25 M sucrose for determination of  PEMT activity by measuring the incorporation of 
radiolabeled methyl groups from S-adenosyl-L-[methyl-3H]methionine into phospholipids 
according to the method of Duce et al. (74) with modifications.  This specific assay using 
endogenous phosphatidylethanolamine (PE) has been shown to accurately determine PEMT 
activity equivalent to methods that add exogenous PE to the incubation mixture (34, 111).  
Briefly, the reaction mixture contained 10 mM HEPES (pH 7.3), 4 mM dithiothreitol, 5 mM 
MgCl2, 0.1 mM SAM, 2 μCi S-adenosyl-L-[methyl-3H]methionine, and 750 μg protein in a 
final volume of 550 μL.  The reaction was initiated by adding 75 μL microsomal protein and 
incubated in a 37°C water bath for 10 minutes.  The reaction was terminated by pipetting 100 
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μL of the assay mixture into 2 mL chloroform: methanol: 2 N HCl (6:3:1, v:v:v), in 
duplicate.  The chloroform phase was washed three times with 1 mL 0.5 M KCl in 50 percent 
methanol, transferred to glass scintillation vials, and allowed to dry at room temperature.  
The lipid fraction was reconstituted in 5 mL Scintiverse® (Fisher Scientific, Pittsburgh, PA) 
scintillation fluid and the radioactivity was determined by liquid scintillation counting.   
Plasma Homocysteine Determination 
Total plasma homocysteine concentrations were analyzed as described by Ubbink et al. 
(278).  Briefly, plasma samples (300 μL) were incubated at 4°C for 30 minutes with 10 
percent tributylphosphine in dimethylformamide (v/v).  N-acetylcysteine (1 mM) was added 
to the plasma samples as an internal standard.  Following termination of the reaction with 
ice-cold 10 percent trichloroacetic acid (w/v) containing 1 mM EDTA, samples were 
centrifuged at 1,000 × g for 5 minutes.  The supernatant fraction was removed and added to a 
solution containing 0.125 M borate buffer (pH 9.5), 1.55 M sodium hydroxide, and 0.1 
percent (w/v) 4-fluoro-7-sulfobenzofurazan (ammonium salt).  Homocysteine was quantified 
using HPLC in conjunction with fluorometric detection as described (198, 230). 
MS and BHMT Activity Analysis 
MS activity was analyzed using the method described by Keating et al. (134).  The assay 
was initiated with 600 μg of protein added to a reaction mixture (200 μL) containing the 
following: 105 mM sodium phosphate buffer (pH 7.5), 0.12 μM cyanocobalamin, 36 mM 
dithiothreitol, 0.3 mM SAM, 8.4 mM β-mercaptoethanol, 8.25 mM DL-homocysteine, and 
0.63 mM [methyl-14C]-THF (0.17 μCi/μmoL).  Following incubation at 37°C for 1 hour, the 
reaction was terminated by adding ice-cold water.  Samples were immediately transferred to 
AG 1-X8 (chloride form) resin columns and effluent fractions collected for liquid 
scintillation counting.  The enzymatic activity of BHMT was determined as previously 
described (92) in duplicate using a reaction mixture containing 40 μg protein, 50 mM Tris-
HCl (pH 7.5), 5 mM DL-homocysteine, and 2 mM betaine (0.05-0.1 μCi).  Following a 1- to-
2-hour incubation at 37°C, samples were chilled, ice-cold water added, and applied to Dowex 
1-X4 columns.  Eluted fractions were collected in scintillation vials and radioactivity was 
measured by liquid scintillation counting.  One unit of BHMT activity was equivalent to the 
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production of 1 nmol of methionine per hour (211).  For both assays, fresh homocysteine was 
prepared daily from the thiolactone derivative (92). 
Determination of GNMT and BHMT mRNA abundance 
Total mRNA was isolated from frozen liver using a commercial reagent kit (RNAeasy™, 
Qiagen) and quantified by UV detection.  Northern blot analysis was performed as described 
previously (255).  Liver RNA was resolved on 1.2 percent (w/v) agarose gels containing 
formaldehyde, transferred to Nytran Super Charge membranes (Schleicher & Schuell, 
Bioscience, Keene, NH) using a Turboblotter (Schleicher & Schuell), and RNAs were 
immobilized by UV-cross-linking.  Membranes were prehybridized in ExpressHyb (BD 
Biosciences Clontech, Palo Alto, CA) and then hybridized with 32P-labeled probes.  The 
GNMT probe was a NdeI/ KpuI restriction fragment from the 3’ end of the rat GNMT in pEt-
17b that was kindly provided by Dr. Zigmund A. Luka, Vanderbilt University Medical 
Center, Nashville, TN.  The BHMT probe was a EcoRI restriction fragment from BHMT 
cDNA (nt 866-1317).  DNA probes were labeled using a Ready-To-Go DNA labeling beads 
(Amersham Biosciences, Piscataway, NJ) and (α-32P) dCTP (3000 Ci/mmol, PerkinElmer, 
Life & Analytical Sciences, Boston, MA).  After hybridization, membranes were washed and 
evaluated by PhosphorImager analysis (Sunnyvale, CA) using ImageQuant software.  To 
normalize RNA expression, membranes were stripped and rehybridized with labeled rat 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probes (Ambion, Inc., Austin, 
TX).   
Measurement of Hepatic Folate Concentrations 
THF and 5-CH3-THF were determined using HPLC and fluorometric detection according 
to Rebello (221) with some minor modifications (208).  Briefly, frozen homogenates were 
thawed and placed in a boiling water bath for 60 minutes and following centrifugation at 
20,000 × g for 10 minutes, rat serum conjugase was added to an aliquot of the resulting 
supernatant and incubated for 1 hour at 37 °C.  Following activation of Sep-Pak NH2 
columns with acetonitrile and 16 mM sodium acetate buffer (pH 4.5), samples were applied 
and washed with acetate buffer and sodium phosphate (100 mM) containing 50 mM 2-
mercaptoethanol.  Folate coenzymes were separated on a phenyl Radial-Pak column (Waters 
Associates, Milford, MA) and quantified using fluorometric detection.   
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Statistical Analysis 
The mean values of each treatment group were analyzed by a two-way ANOVA using 
SigmaStat software (SPSS, Chicago, IL) at a significance level of 5 percent and compared 
using Fisher’s least significant difference procedure (254).  Mean GNMT and BHMT mRNA 
values in control and diabetic rats were analyzed by a Student’s t-test (p≤ 0.05). 
Results 
Confirmation of differential folate status and a diabetic state in rats.  Neither STZ 
treatment nor dietary folate levels had a significant effect on the weight gain (Table 4.2).  
Blood glucose concentrations in STZ-treated rats were approximately 2-fold greater in all 
diet groups compared to their respective controls, regardless of dietary folate levels.  Control 
rats fed the folate-deficient diet exhibited an 84 percent reduction in total hepatic folate 
coenzyme concentrations, whereas they were increased 56 percent by folate supplementation 
(FD, 1.18 ± 0.11; F, 7.37 ± 0.92; FS, 11.53 ± 0.94 nmol/g liver).  Taken together, the data 
indicates that rats were in a moderate state of diabetes and altered folate status.  
Folate-containing diets attenuated GNMT activity in diabetic rats, but was without effect 
on abundance.  Mild folate deficiency in diabetic rats resulted in a 200 percent induction of 
GNMT activity as compared to non-diabetic controls (Figure 4.2A).  However, this 
induction was significantly attenuated 64 and 74 percent in treatment groups fed the folate-
adequate and folate-supplemented diets, respectively, compared to diabetic rats fed a folate-
deficient diet.  In contrast, GNMT abundance was elevated to the same extent in all diabetic 
rats regardless of dietary folate (Figure 4.2B).  Taken together, these results indicate that 
adequate dietary and subsequently hepatic folate concentrations attenuated the diabetes-
mediated increase in GNMT activity, likely by posttranslational control.     
Hyperhomocysteinemia in folate-deficient rats was attenuated by streptozotocin (STZ)-
induced diabetes.  Folate-deficient animals exhibited a 4- to 5-fold increase in total plasma 
homocysteine concentrations compared to animals fed either the folate-adequate or folate-
supplemented diet (Figure 4.3).  However, homocysteine levels in folate-deficient diabetic 
rats were only 54 percent of that exhibited by non-diabetic rats.  As expected, normal 
homocysteine concentrations were observed in folate-adequate and folate-supplemented 
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control rats.  The lower mean homocysteine concentrations in diabetic rats provided an 
adequate or supplemented folate diet were similar. 
Diabetes elevated the hepatic activity of PEMT and BHMT, whereas MS activity was 
diminished in diabetic rats.  The enzymatic activity of PEMT was determined as it is a major 
user of methyl groups from SAM, thereby reflecting methyl group homeostasis, as well as a 
regulator of homocysteine balance.  As shown in Table 4.3, the activity of SAM-dependent 
PEMT was increased ~2-fold in all diabetic rats, regardless of dietary folate.  The enzymatic 
activity of the two hepatic enzymes required for folate-dependent and folate-independent 
remethylation of homocysteine, MS and BHMT, respectively, are also shown in Table 2.  A 
diabetic state differentially altered the activity of these enzymes.  For all of the folate diet 
groups, BHMT activity was increased approximately 1.5- to 2-fold compared to their 
respective non-diabetic controls.  Conversely, STZ treatment reduced MS activity 23-46 
percent compared to control values. 
GNMT and BHMT mRNA abundance were increased in diabetic rats.  The elevated 
activity of BHMT and GNMT in diabetic rats was reflected in the abundance of their 
respective mRNAs.  GNMT and BHMT mRNA levels were elevated 6.5- and 1.9-fold in 
diabetic rats, respectively, compared to the non-diabetic animals (Figure 4.4).  
Discussion 
Understanding the nutritional and/or physiologic factors that modulate folate, 
homocysteine, choline, and methyl group metabolism is critical towards the prevention of 
numerous pathologies associated with perturbation of these pathways (132, 227, 240).  We 
have shown previously (198) that a type 1diabetic state results in modulation of methyl group 
metabolism by increasing the enzymatic activity and protein abundance of GNMT, a key 
hepatic protein in the regulation of methyl group supply from the folate-dependent one 
carbon pool and its utilization for SAM-dependent transmethylation reactions.  Because 
induction of GNMT function would be expected to result in a loss of methyl groups as well 
as contribute to homocysteine production, developing intervention strategies directed at 
restoring normal GNMT function is important.  Thus, the aim of this research was to 
determine the impact varying degrees of folate status has on diabetes and methyl group 
metabolism, particularly as the folate coenzyme 5-CH-3-THF allosterically inhibits GNMT 
 64 
 
activity (291, 292).  Moreover, we also examined the effects of a diabetic state on additional 
aspects of SAM-dependent metabolism of methyl groups and choline, namely phospholipid 
methylation. 
A lack of dietary folate clearly resulted in the highest activity of GNMT in diabetic rats 
without altering the abundance of the protein.  Because GNMT was attenuated in diets 
containing adequate or supplemental folate, together these results would indicate that 
modulation of GNMT activity, as expected, was at a posttranslational level as a result of 
diminished 5-CH3-THF concentrations.  We have found similar results for retinoic acid-
mediated induction of GNMT in rats fed a folate-deficient diet (VE Knoblock and KL 
Schalinske, unpublished data).  Although these results would suggest that adequate folate 
status has a positive effect under diabetic conditions, supplemental folate did not confer any 
added benefit.  Providing folate at levels ~20-fold greater than our studies here, others have 
shown that folate supplementation by injection was an effective means to reduce embryo 
malformations in diabetic rats (299).  Thus, it will be important in future research to 
determine if a greater reduction in GNMT activity can be achieved with higher doses of 
folate, route of supplementation, and/or longer treatment times. 
The marked hyperhomocysteinemia exhibited in the folate-deficient rats was surprising, 
given that the degree of folate deficiency would appear to be moderate.  This assessment is 
based on the findings that no changes were seen in growth and an antibiotic was not added to 
the drinking water to eliminate bacterial folate production.  A similar 4-wk study design with 
the inclusion of an antibiotic resulted in only a 2-fold increase in plasma homocysteine 
concentrations (117).  However, we found that hepatic folate concentrations were only 16 
percent of that observed for folate adequate rats.  Hyperhomocysteinemia in folate-deficient 
rats was significantly attenuated as a result of diabetes, likely the result of an increase in 
BHMT activity.  Our previous work and others have shown that a diabetic condition can also 
reduce circulating homocysteine levels as a result of increased homocysteine catabolism via 
CBS (123, 198, 219).  In contrast to previous studies (123, 198, 219), hypohomocysteinemia 
was not statistically evident in folate-adequate or folate-supplemented rats receiving an 
amino acid-defined diet.  
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We have extended our previous work by demonstrating that the induction of GNMT and 
BHMT is reflected in the abundance of their respective mRNAs.  It is not known what signal 
results in increased mRNA of these proteins, either by a transcriptional mechanism or 
through mRNA stability.  Previous studies have shown that various hormones (e.g., 
dexamethasone) and relevant metabolites (e.g., methionine, SAM) have the ability to directly 
regulate the expression of these proteins (46, 228, 230).  Ultimately, the induction of GNMT 
and BHMT would be expected to have an impact on other SAM-dependent 
methyltransferases and choline metabolism, respectively. 
For humans, there are numerous reports in the literature that have found both type 1 and 
type 2 diabetes are associated with hyperhomocysteinemia, thereby establishing a potential 
link to increased cardiovascular disease risk (114, 183, 216, 224).  The 
hypohomocysteinemia that has been reported by our laboratory and others (123, 198, 219) is 
likely due to the role of the kidneys in homocysteine metabolism.  The progression from a 
hypo- to a hyperhomocysteinemic state may be the result of renal dysfunction (216), as the 
kidneys play a significant role in the metabolism of homocysteine (26, 80).  Taken together 
with the findings reported here, it is clear that future research will need to be directed at 
understanding the tissue-specific temporal changes in methyl group and homocysteine 
metabolism as a function of diabetes progression.  This knowledge will be vital in the 
development of dietary and/or therapeutic intervention strategies aimed at preventing 
disruption of these pathways by a diabetic condition.   
A novel finding reported here is the up-regulation of the enzymatic activity of PEMT by 
diabetes.  There are numerous studies that have examined the impact of a diabetic state on 
the regulation of PEMT activity and PC synthesis; however, the reports are conflicting and 
appear to vary depending on the animal model, method for inducing diabetes, and the type of 
tissues examined (36, 45, 270, 307).  The action of PEMT constitutes a major route for 
utilization of the labile methyl groups from SAM (126) and thus would be expected to 
provide some index of methyl group availability.  Moreover, PEMT is responsible for ~30 
percent of PC production with the remainder being derived directly from choline pools.  Our 
observed increase in PEMT activity may reflect a shift from using PE, rather than choline 
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directly, for PC synthesis owing to the loss of choline, as betaine, for BHMT and 
homocysteine remethylation. 
PEMT expression and function has been reported to significantly influence homocysteine 
production and secretion (200, 249).   Moreover, it has been proposed to represent a more 
significant use for SAM-derived methyl groups, as opposed to SAM-dependent synthesis of 
creatine (126).  These previous studies reported that homocysteine secretion positively 
associated with inducing expression of PEMT in hepatoma cells, and a complete lack of 
PEMT expression resulted in low circulating levels of homocysteine in PEMT knockout mice 
(200, 249).  Similarly, a 2-fold increase in PEMT activity, similar to the elevation we have 
observed in diabetic rats, in CTP:phosphocholine cytidylytransferase-α knockout mice also 
resulted in an increase in homocysteine production and secretion (126).  Thus, the absence of 
PEMT expression or increasing its expression in cells that have low levels of expression 
appears to regulate homocysteine balance.  However, our studies indicate that an increase in 
hepatic PEMT activity in vivo, as the result of a diabetic state, does not have a concomitant 
alteration in circulating homocysteine levels.  It is likely that the diabetes-mediated increase 
in PEMT, as well as GNMT, does result in an increase in homocysteine production, but 
stimulation of BHMT expression is a compensatory mechanism to prevent homocysteine 
pools from accumulating.  Moreover, irreversible catabolism of homocysteine by the 
transsulfuration pathway and the initial action of CBS has been shown to be activated by 
diabetes and glucocorticoids (123, 219). 
The collective induction of PEMT, GNMT, and BHMT, combined with diminished MS 
activity, indicates that diabetes is characterized by a deficiency of methyl groups and an 
increased requirement for choline.  This is supported by our preliminary studies that found 
the hepatic synthesis of creatine was significantly decreased ~50 percent in diabetic rats (CS 
Hartz and KL Schalinske, unpublished observations), indicating that the induction of GNMT 
and PEMT results in a deficiency of adequate methyl groups for other SAM-dependent 
transmethylation reactions.  To that extent, we have found that diabetes is characterized by 
hypomethylation of DNA in rat liver (303).  The utilization of PC for bile secretion is greatly 
enhanced in the diabetic state (288) and PC requirements correlate to PEMT activity (122).  
Studies that focus on the measurement of metabolic flux through these pathways, similar to 
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what has been recently reported (62, 65), needs to be performed to definitively evaluate the 
effect of diabetes. Recently, a kinetic study with human subjects demonstrated that 
transmethylation, homocysteine transsulfuration, and clearance of homocysteine were 
significantly reduced in type 2 diabetes with nephropathy (271). 
It is also clear from our findings that the observations reported here are specific for a 
diabetic state and not the result of using a chemically-induced model.  This is supported by 
the fact that we, and others, have found similar changes using an either alloxan-mediated 
model, or treating rats and cultured hepatoma cells with dexamethasone (230, 307, 310).  
Most recently, we have also demonstrated that treatment of STZ-diabetic rats with insulin 
prevented the induction of GNMT and PEMT, and restored circulating homocysteine 
concentrations to normal levels (199) (Chapter 3). 
In summary, we have shown that type 1 diabetes results in the metabolic disruption of 
methyl groups, choline, and homocysteine, and folate status has an impact on these findings.  
This may have significant implications with respect to the nutritional needs of patients with 
type 1 diabetes.  Importantly, many of these metabolic findings with respect to type 1 
diabetes have also been recently noted in a type 2 diabetes model (299).  For humans with 
diabetes, additional factors that will clearly play a significant role in modulating methyl 
group and homocysteine metabolism include other moderate B-vitamin (e.g., B12 and B6) 
deficiencies and/or expression of polymorphic enzymes, such as MTHFR.      
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Tables 
Table 4.1 
Standard Amino Acid Defined Diet (F) 1 
Diet Constituent g/kg Diet Constituent g/kg 
L-Alanine 3.5 Corn Starch 150.0 
L-Arginine 12.1 Maltodextrin 150.0 
L-Asparagine 6.0 Cellulose 30.0 
L-Aspartic Acid 3.5 Soybean Oil 80.0 
L-Cystine 3.5 Mineral Mix2 35.0 
L-Glutamic Acid 40.0 Calcium Phosphate Monobasic 8.2 
Glycine 23.3 Choline Bitartrate 2.5 
L-Histidine 4.5 Niacin3 0.03 
L-Isoleucine 8.2 Calcium Pantothenate3 0.016 
L-Leucine 11.1 Pyridoxine HCl3 0.007 
L-Lysine HCl 18.0 Thiamin HCl3 0.006 
L-Methionine 8.2 Riboflavin3 0.006 
L-Phenylalanine 7.5 Folic Acid3,4 0.002 
L-Proline 3.5 Biotin3 0.0002 
L-Serine 3.5 Vitamin B12 (0.1% in mannitol)3 0.025 
L-Threonine 8.2 DL-α Tocopheryl Acetate (500 IU/g)3 0.15 
L-Tryptophan 1.8 
Dry Vitamin A 
Palmitate (500,000 
U/g)3 
0.008 
L-Tyrosine 5.0 
Vitamin D3, 
cholecalciferol 
(500,000 U/g)3 
0.002 
L-Valine 8.2 Vitamin K, phylloquinone3 0.0008 
Sucrose 364.429 TBHQ (antioxidant) 0.02 
1The folate-adequate diet (F) was a custom research diet developed by Harlan Teklad 
(TD.03333, Madison, WI). 
2Mineral Mix, AIN-93M-MX (TD 94049). 
3Diet constituents are part of vitamin mix AIN-93-VX (TD 94047). 
4Folate-deficient (FD, TD.03428) and folate-supplemented (FS, TD.03429) diets were 
modified by excluding folate and adding 6 ppm folate, respectively. 
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Table 4.2 
Cumulative weight gain, blood glucose concentrations, and hepatic folate 
concentrations in rats treated with streptozotocin (STZ) and fed either 0 (FD), 2 (F), or 8 
(FS) ppm dietary folate1 
 
  
1Values are means ± SE; n = 6.  Different letters within a column indicates 
a significant difference, p ≤ 0.05. 
 Weight Gain (g) 
Plasma glucose 
(mM) 
FD 143 ± 12a 10.4 ± 0.7a 
FD + STZ 122 ± 7a 21.5 ± 2.7b 
F 144 ± 19a 11.5 ± 0.8a 
F + STZ 137 ± 5a 20.9 ± 2.0b 
FS 131 ± 13a 10.1 ± 1.2a 
FS + STZ 128 ± 3a 21.8 ± 1.5b 
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Table 4.3 
Hepatic activity of the SAM-dependent methyltransferase PEMT and homocysteine 
remethylation enzymes BHMT and MS in rats treated with streptozotocin (STZ) and fed 
either 0 (FD), 2 (F), or 8 (FS) ppm dietary folate1 
 
PEMT* 
(pmol/min·mg 
protein) 
BHMT 
(U/mg protein) 
MS 
(pmol/min⋅mg 
protein) 
FD 29.1 ± 1.2a 63 ± 6a 54 ± 5a 
FD + STZ 55.9 ± 11.5b 114 ± 16c 29 ± 3c 
F 31.5 ± 2.3a 58 ± 6a 47 ± 6a,b 
F + STZ 58.9 ± 6.4b 91 ± 14b 36 ± 6b,c 
FS 31.6 ± 2.7a 51 ± 4a 50 ± 6a,b 
FS + STZ 69.1 ± 6.2b 93 ± 6b,c 31 ± 3c 
1Values are means ± SE; n = 6.  Different letter superscripts within a column indicate a 
significant difference, p ≤ 0.05.  *Abbreviations: BHMT, betaine homocysteine S-
methyltransferase; MS, methionine synthase; PEMT, phosphatidylethanolamine 
N-methyltransferase. 
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Figure Legends 
Figure 4.1  
Folate, homocysteine, choline and methyl group metabolism.  The primary methyl donor 
S-adenosylmethionine (SAM) provides methyl groups for numerous of methyltransferase 
reactions including: the conversion of glycine to sarcosine by glycine N-methyltransferase 
(GNMT), the synthesis of phosphatidylcholine (PC) from phosphatidylethanolamine (PE) by 
phosphatidylethanolamine N-methyltransferase (PEMT), and creatine phosphate production 
by the action of guanidoacetate methyltransferase (GAMT).  S-adenosylhomocysteine (SAH) 
results following methyl group donation and is subsequently hydrolyzed to homocysteine by 
SAH hydrolase (SAHH).  Homocysteine can either be further catabolized by the 
transsulfuration pathway to cysteine, by the activity of cystathionine β-synthase (CBS) and γ-
cystathionase, or remethylated back to methionine.  Homocysteine remethylation occurs by 
the folate-independent pathway and the activity of betaine-homocysteine-S-methyltransferase 
(BHMT), or through the folate-dependent activity of methionine synthase (MS), a B12-
dependent enzyme that reduces 5-methyltetrahydrofolate (5-CH3THF) to tetrahydrofolate 
(THF).  The majority of one-carbon groups for the folate-dependent one-carbon pool 
originate from serine and serine hydroxymethyltransferase (SHMT) to generate 5,10-CH2-
THF, which can then undergo irreversible reduction to 5-CH3-THF by the action of 5,10-
CH2-THF reductase (MTHFR).    
Figure 4.2 
Induction of hepatic glycine N-methyltransferase (GNMT) in streptozotocin (STZ)-
mediated diabetic rats.  Rats were fed a diet consisting of 0 ppm (folate-deficient, FD), 2 ppm 
(folate-adequate, F) or 8 mg folate/ kg diet (folate-supplemented, FS) for a period of 35 days.  
A single dose of streptozotocin (STZ, 60 mg/kg body weight) was administered on day 30.  
Liver samples were collected and the activity and abundance of GNMT was determined as 
described under “Materials and Methods”.  A: GNMT activity in diabetic and non-diabetic 
rats fed the various folate diets.  Data are expressed as means ± S.E. (n = 6) and bars denoted 
with different letters are significantly different (p ≤ 0.05).  B: GNMT abundance in diabetic 
and non-diabetic rats fed the various folate diets.  A monoclonal GNMT antibody (24) was 
used for Western blot analysis, and a representative immunoblot is shown.  Data are 
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expressed as means ± SE (n = 6) and displayed as a percent of the mean of the control group.  
Bars denoted with different letters are significantly different (p ≤ 0.05). 
Figure 4.3 
Hyperhomocysteinemia in folate-deficient rats was attenuated by streptozotocin (STZ)-
mediated diabetes.   Plasma samples from the same rats as described for Figure 4.2 were 
obtained for the determination of total homocysteine concentrations by HPLC and 
fluorometric detection as described under “Materials and Methods”.  Data are expressed as 
means ± SE (n = 6) and bars denoted with different letters are significantly different 
(p≤0.05). 
Figure 4.4   
GNMT and BHMT mRNA abundance were increased in streptozotocin (STZ)-mediated 
diabetic rats.  Liver samples from the same rats as described for Figure 4.2 were collected for 
the isolation of total RNA.  The abundance of GNMT and BHMT mRNA was determined by 
Northern blot analysis as described under “Materials and Methods”.  Data are expressed as 
means ± SE (n = 3-9).  * P ≤ 0.05 vs. non-diabetic values.  GNMT and BHMT mRNA 
abundance values were normalized to GAPDH mRNA abundance for each sample. 
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CHAPTER 5: VITAMIN D SUPPLEMENTATION MAINTAINS 
NORMAL HOMOCYSTEINE METABOLISM IN DIABETIC RATS 
 
Modified from an abstract published in the Federation of American Societies for 
Experimental Biology Journal1 
 
Abstract 
A diabetic state is known to disrupt both methyl group and homocysteine metabolism.  
Recent studies indicate acute diabetes leads to both an induction of glycine-N-
methyltransferase (GNMT), a key regulatory enzyme in methyl group metabolism, and 
hypohomocysteinemia.  However, as kidney function deteriorates hyperhomocysteinemia 
results in chronic diabetes, a link to complications such as cardiovascular disease.  A number 
of nutrients have been identified as modifiers of diabetic pathogenesis including vitamin D.  
Studies have reported increased insulin sensitivity and a reduction in blood glucose with 
vitamin D supplementation.  Supplementation with vitamin D has been shown to prevent 
development of type 1 diabetes in genetic mouse model, whereas vitamin D deficiency has 
been shown to increase the risk for diabetic pathogenesis.  Therefore, this study was 
conducted to determine if vitamin D supplementation restores normal methyl group and 
homocysteine metabolism in diabetic rats.  Rats were randomly assigned to one of four 
groups: control, streptozotocin-induced diabetic (STZ, 60 mg/kg BW), vitamin D (D, 
calcitriol, 500 ng/kg BW), or both (D+STZ).  Vitamin D supplementation prevented 
hypohomocysteinemia in diabetic rats, which is likely due to an induction of GNMT.  It did 
not prevent other diabetes-mediated alterations in homocysteine remethylation or 
transsulfuration.  Taken together, it appears that vitamin D supplementation may be of 
benefit by maintaining normal homocysteine metabolism when disrupted by a diabetic state, 
resulting from increased production of homocysteine. 
Introduction 
The metabolism of folate, methyl groups, and homocysteine are key interrelated pathways 
involved in optimal health and disease prevention.  Thus, disruption of these metabolic 
pathways risk development of a number of pathologies including cancer, vascular disease, 
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and neural tube defects (132, 227, 240).  Methyl groups are most often provided in the diet 
(i.e. methionine and choline) or endogenously from the folate-dependent one-carbon pool.  In 
the form of methionine, adenylation activates this amino acid forming S-adenosylmethionine 
(SAM), the primary methyl group donor in over 50 known mammalian transmethylation 
reactions (194, 289) (Figure 5.1).  S-adenosylhomocysteine (SAH) results following methyl 
group donation in biosynthetic- and modification-type reactions, such as nucleic acids and 
specialized proteins (X→X-CH3).  The production of phosphatidylcholine (PC) from 
phosphatidylethanolamine (PE) constitutes a major consumption of SAM-derived methyl 
groups through the activity of phosphatidylethanolamine N-methyltransferase (PEMT) 
activity (256).  Thus PEMT is considered to be a major contributor to homocysteine 
production.  Studies indicate that PEMT is regulated based on the need for PC and very low 
density lipoprotein secretion (122, 201) as well as homocysteine production (249).  SAH is a 
potent inhibitor of SAM-dependent transmethylation reactions (40) making it vital to 
optimize the SAM:SAH ratio.  This regulation is accomplished by the abundant tissue-
specific cytosolic protein GNMT, in the conversion of glycine to sarcosine (135, 289, 310).  
SAH is hydrolyzed to homocysteine by SAH hydrolase (SAHH) (40).  At this point 
homocysteine has two potential fates, remethylation to methionine or transsulfuration to 
cysteine. 
SAM-dependent DNA methylation is catalyzed by a family of DNA methyltransferases 
(DNMTs) (156), which transfer a methyl group to cytosine in CpG dinucleotides.  Epigenetic 
modification of DNA by methylation also requires methyl groups from SAM; as a result 
methylation status is an indicator of methyl group supply.  DNA methylation is a critical tool 
in epigenetic modification, regulating the tissue-specific expression of certain genes, and 
ultimately genome function (222).  CpG islands are usually clustered in gene promoter 
regions, thus methylation often results in regulation of DNA expression, typically repression 
(130).  Aberrant DNA methylation is also associated with a number of pathologies.  
Preneoplastic and tumor DNA is characterized by global hypomethylation, regional 
hypermethylation, and increased activity of DNMTs (20, 129, 151).  Development of 
atherosclerotic lesions has also been associated with changes in DNA methylation (73, 110). 
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Remethylation of homocysteine to methionine occurs by two means, folate-independent 
or folate-dependent pathways, each equally contributing to the remethylation of 
homocysteine (85).  A methyl group is donated by 5-methyl tetrahydrofolate (5-CH3THF) in 
the folate-dependent remethylation of homocysteine to methionine.  This reaction, catalyzed 
by the B12-dependent enzyme methionine synthase (MS), results in tetrahydrofolate (THF) 
(248).  Folate-independent remethylation of homocysteine occurs through the methyl donor 
betaine, which is formed following the oxidation of choline.  This reaction is catalyzed by 
betaine homocysteine S-methyltransferase (BHMT), forming dimethylglycine and 
methionine (81, 92). 
Homocysteine can also be irreversibly catabolized to cysteine through the oxidative 
transsulfuration pathway.  Transsulfuration is accomplished by the activity of two B6-
dependent enzymes.  Initially, cystathionine β-synthase (CBS) condenses homocysteine with 
serine forming cystathionine.  Finally cystathionine is hydrolyzed to cysteine and α-
ketobutyrate by γ-cystathionase (116, 147).  Ultimately cysteine can be used to synthesize 
useful compounds such as glutathione, taurine, and pyruvate (260, 262).  Thus measuring any 
of these metabolites would indicate relative homocysteine catabolism.  Increased plasma 
homocysteine (271), is recognized as an independent risk factor for the development of 
vascular disease (31, 55, 132). 
A number of factors (i.e. nutritional, hormonal, pharmacological, pathological, 
environmental, and genetics) have been identified as having the ability to influence 
homocysteine and methyl group metabolism.  A diabetic state, characterized by a reduction 
of insulin levels and an elevation in circulating counter-regulatory hormones to insulin (i.e. 
glucagon and glucocorticoids) (304), has been indentified in the disruption of homocysteine 
and methyl group metabolism.  In both type 1 and 2 diabetes without renal complications 
hypohomocysteinemia has been reported in humans and rats (8, 123, 198, 224, 299).  Similar 
findings have been reported in animals treated with glucocorticoids and glucagon (124, 219, 
230).  Hypohomocysteinemia likely results from increased transsulfuration as evidenced by 
increased CBS activity, protein, and mRNA levels as well as γ-cystathionase activity (198, 
219, 299).  Folate-independent remethylation via BHMT may also play a role in reducing 
homocysteine, as its activity and mRNA levels have also been reportedly increased in acute 
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diabetes (197, 198, 220, 299).  As reported in the following chapter and additional studies, 
insulin prevented hypohomocysteinemia in the STZ-induced type 1 diabetic rat (123, 199, 
219).  However, in type 1 and 2 diabetics, as renal function declines homocysteine levels rise 
(53, 118, 216).  The hyperhomocysteinemic state that results may be attributed to decreased 
clearance of the sulfur-containing amino acid (271). 
A growing collection of evidence indicates a relationship between vitamin D and 
diabetes.  In NOD mice, treatment with the metabolically active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3 or calcitriol), prevented the onset of type 1 diabetes (175, 
315).   It has also been suggested that increasing vitamin D intake as early as infancy, may 
decrease the risk of the child developing type 1 diabetes later in life (121).  Moreover vitamin 
D deficiency seemingly accelerates diabetes onset in NOD mice (96).  In type 2 diabetic 
humans and animals, vitamin D deficiency has been reported to inhibit insulin secretion and 
impair glucose tolerance (54, 93, 202).  Furthermore, vitamin D repletion seems to 
ameliorate the noted abnormalities in insulin secretion and glucose tolerance (131, 203) and 
glucose concentrations in type 2 diabetic rats were reduced by 40% with vitamin D3 
supplementation (69).  Epidemiological evidence has also indicated that serum 25-
hydroxyvitamin D3 levels, the primary circulating form of vitamin D, are inversely correlated 
with the development of type 2 diabetes and insulin resistance (243). 
Clearly, vitamin D status plays a role in the development and progression of both type 1 
and 2 diabetes.  Interestingly, as mentioned above, vitamin D promotes insulin secretion, 
which is also a known regulator of homocysteine metabolism.  Thus, this study was aimed at 
determining if calcitriol supplementation could prevent diabetes-altered methyl group and 
homocysteine metabolism.   
Materials & Methods 
Chemicals 
 Reagents used in the research methods were obtained from the following sources: S-
adenosyl-L-[methyl-3H]methionine, PerkinElmer Life Sciences; chemiluminescent Western 
blotting detection reagents, GE Healthcare; streptozotocin and S-adenosyl-L-methionine, 
Sigma-Aldrich; goat anti-rabbit IgG horseradish peroxidase, Southern Biotechnology; 
calcitriol, Biomol, Inc.; HpaII endonuclease, New England Biolabs Inc.; [3H]-dCTP, NEN 
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Life Science Products; GNMT polyclonal antibody and goat anti-chicken IgY horseradish 
peroxidase, Aves Labs, Inc.  Jan Kraus, University of Colorado Health Sciences Center, 
generously provided the CBS polyclonal antibody.  All other chemicals were of analytical 
grade. 
Animals 
Experiments involving animals were approved by and conducted in accordance with the 
Iowa State University Laboratory Animal Resources guidelines.  Male Sprague-Dawley rats 
(125-149 grams) were obtained from Harlan Sprague-Dawley and housed in separate cages 
with a 12-hour light: dark cycle.  Animals were allowed food and water ad libitum.  Rats 
were acclimated to their diet (230) for 11 days and then randomly assigned to one of four 
treatment groups: control, diabetic (STZ), vitamin D-supplemented (D), and vitamin D-
supplemented diabetic (D+STZ).  Rats received an oral dose of 1, 25(OH)2D3 (500 ng/kg 
body weight) or the vehicle corn oil, beginning on day 12 of experiment and every other day 
until the end of the experiment.  On day 21, the animals received a single intraperitoneal 
injection of either STZ (60 mg/kg body weight) or the vehicle (10 mM citrate buffer, pH 
4.5).  Animals were anesthetized on day 27 with a mixture of ketamine:xylazine (90:10 
mg/kg body weight) and heparinized whole blood was collected by cardiac puncture.  An 
aliquot was removed for the determination of blood glucose concentrations using a 
commercial kit (Sigma-Aldrich).  The remaining whole blood was centrifuged at 5,000 × g 
for 5 minutes and the plasma was removed and stored at -20°C for subsequent determination 
of homocysteine concentrations.  Immediately following blood collection, portions of the 
liver were removed and homogenized in ice-cold buffer containing 10 mM sodium phosphate 
(pH 7.0), 0.25 M sucrose, 1 mM EDTA, 1 mM sodium azide, and 0.1 mM 
phenylmethylsulfonyl fluoride.  Homogenates were centrifuged at 20,000 × g for 30 minutes 
and an aliquot of the supernatant was stored at -70°C for the subsequent determination of 
GNMT activity and abundance, MS activity, BHMT activity, and CBS abundance.  An 
additional aliquot was removed and centrifuged at 100,000 x g.  The pellet was collected for 
analysis of PEMT activity, resuspended in 0.25 M sucrose buffer, and stored at -70°C.  
Additional portions of the liver were collected and snap-frozen in liquid nitrogen for DNA 
isolation and methylation analysis.  Total soluble protein concentration of the cytosolic and 
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microsomal fractions were determined using a commercial kit (Coomassie Plus, Pierce) 
based on the Bradford method (32) and bovine serum albumin as the standard.   
Plasma Glutathione and Homocysteine Determination 
Total plasma homocysteine and glutathione concentrations were analyzed as described by 
Ubbink et al. (278).  Breifly, plasma thiol samples (300 μL) were derivatized with 10% (v/v) 
tributylphosphine in dimethylformamide and incubated at 4°C for 30 minutes.  N-
acetylcysteine (1 mM) was also added to each sample as an internal standard.  Following 
termination of the reaction with ice-cold 10% (w/v) trichloroacetic acid containing 1 mM 
EDTA, samples were centrifuged at 1,000 × g for 5 minutes.  The supernatant was removed 
and added to a solution containing 0.125 M borate buffer (pH 9.5), 1.55 M sodium 
hydroxide, and 0.1% (w/v) 4-fluoro-7-sulfobenzofurazan (ammonium salt).  HPLC was used 
with fluorometric detection to quantify homocysteine by injecting the derivatized samples on 
to a μ-Bondapak C18 Radial-Pak column (Waters Associates) equilibrated with 4% (v/v) 
acetonitrile in 0.1 M monobasic potassium phosphate buffer (pH 2.1) (198, 230). 
GNMT Activity Determination 
 The enzymatic activity of GNMT was measured based on the method of Cook and 
Wagner (60).  The assay was performed in triplicate using 250 μg protein and a reaction 
mixture containing the following: 200 mM Tris buffer (pH 9.0), 2 mM glycine, 5 mM 
dithiothreitol, and 0.2 mM S-adenosyl-L-[methyl-3H]methionine.  Samples were then 
incubated for 30 minutes at 25°C.  Following incubation, 10% (w/v) trichloroacetic acid in 
0.1 M acetic acid was added to stop the reaction, followed by activated charcoal (78 mg/mL) 
to absorb the unreacted SAM.  Samples were centrifuged at 14,000 x g for 5 minutes and 200 
μL of the supernatant was removed for liquid scintillation counting.   
CBS and GNMT Abundance Determination 
The abundance of CBS and GNMT were determined using immunoblotting methods as 
described (230).  A 15% (w/v) SDS-polyacrylamide gel was polymerized and utilized to 
quantify the 32-kDa subunit of GNMT and the 63-kDa subunit of CBS using electrophoresis.  
Proteins were then transferred to nitrocellulose paper and incubated with a 1:50,000 dilution 
of the primary CBS antibody (rabbit) and a 1:5000 dilution of the primary GNMT antibody 
(chicken), overnight at 4°C.  The next day the membrane was incubated with a 1:5000 
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dilution of either a goat anti-rabbit IgG horseradish peroxidase secondary antibody or a goat 
anti-chicken IgY horseradish peroxidase secondary antibody for one hour at room 
temperature.  Proteins were detected using chemiluminescence and multiple exposures to 
Kodak X-Omat AR film.  Band density was assessed using Quantity one® software (Biorad).   
BHMT and MS Activity Analysis 
BHMT activity was measured as previously described by Garrow (92).  The standard 
assay mixture contained 5 mM DL-homocysteine, 2 mM betaine (0.1 μCi), and 40 μg total 
protein.  BHMT activity is expressed as units/mg protein, where 1 unit is equivalent to 1 
nmol of methionine formed per hour.  The activity of MS was determined as previously 
described (134).  The assay reaction mixture containing 500 mM sodium phosphate buffer 
(pH 7.5), 1.3 μM  cyanocobalamin, 1M dithiothreitol, 10 mM SAM, 82.4 mM β-
mercaptoethanol, 100 mM homocysteine, and 15 mM [methyl-14C]-THF (0.17 μCi/μmol), 
was added to liver supernatants and incubated for one hour at 37°C.  Ice-cold water was 
added to stop the reaction and the assay mixture was immediately applied to an AG 1-X8 
(chloride form) resin column.  Effluent fractions (3 mL deionized water) were collected for 
subsequent liquid scintillation counting.  Homocysteine was prepared fresh daily from a 
thiolactone derivative for both activity assays. 
Determination of PEMT Activity 
PEMT activity was determined by measuring the incorporation of radiolabeled methyl 
groups from S-adenosyl-L-[methyl-3H]methionine into phospholipids by the methods of 
Duce et al. (74).  The reaction mixture contained 10 mM HEPES (pH 7.3), 4 mM 
dithiothreitol, 5 mM MgCl2, 0.1 mM SAM, 2 μCi S-adenosyl-L-[methyl-3H]methionine, and 
600 μg protein in a final volume of 550 μL.  The reaction was initiated by adding 600 μg 
microsomal protein (10 μg/μL) to the assay mixture and incubated in a 37°C water bath for 
15 minutes.  The reaction was terminated by transferring 100 μL of the assay mixture into 2 
mL chloroform: methanol: 2 N HCl (6:3:1, v:v:v) in duplicate.  The chloroform phase was 
washed with 0.5 M KCl in 50% (v/v) methanol, transferred to glass scintillation vials, and 
allowed to dry at room temperature overnight.  The following day, 5 mL scintillation fluid 
was added to each vial and the samples were then subjected to liquid scintillation counting.   
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Determination of Global DNA Methylation 
Global hepatic DNA methylation was determined using an assay that measures in vitro 
incorporation of methyl groups into global DNA as described by Pogribny et al. (215), with 
minor modifications.  DNA was purified from liver samples (186) using a commercial kit 
(Promega).  The DNA (1.25 μg) was then digested using HpaII endonuclease (New England 
Biolabs, Inc.).  The DNA extension assay mixture consisted of 1.0 μg digested DNA, 1X 
PCR Buffer II, 1mM magnesium chloride, 0.5 U AmpliTaq DNA polymerase (Applied 
Biosystems), and 9.3 μM [3H]-dCTP (NEN Life Science Products) in a total volume of 40 
μL.  Following a one hour incubation period at 55°C, samples were applied to DE81 ion 
exchange filter paper, washed with 0.5M sodium phosphate buffer, dried, and quantified via 
liquid scintillation counting.  The extent of [3H]-dCTP incorporation, as measured by 
scintillation counting, was considered directly proportional the number of originally 
unmethylated sites (215). 
Statistical Analysis 
The mean values of each treatment group were analyzed by two-way ANOVA using 
SigmaStat software (SPSS) at a significance level of 5 percent.  When the variance between 
means was significant, mean values were compared using Fisher’s least significant difference 
procedure (254).  
Results 
Weight gain nor blood glucose concentrations were altered by vitamin D treatment.  
Diabetic rats gained significantly less weight as compared to control animals, 65% and 59% 
respectively (Table 5.1).  Further vitamin D supplementation did not affect weight gain 
within the diabetic and non-diabetic groups.  Blood glucose concentrations were 
approximately 3-fold greater in STZ-treated rats regardless of vitamin D supplementation, 
indicating overt diabetes.  Vitamin D supplementation did not significantly alter blood 
glucose concentrations in diabetic or non-diabetic rats compared to their respective controls.     
Vitamin D supplementation restores homocysteine concentrations in diabetic rats.  There 
was a marked decrease in plasma homocysteine concentrations in diabetic rats (Figure 5.2).  
Diabetic rats exhibited only 40% of the plasma homocysteine concentrations evident in 
control animals.  Moreover, the hypohomocysteinemia that resulted in diabetic rats was 
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prevented by vitamin D supplementation.  Vitamin D alone resulted in no significant change 
in plasma homocysteine concentrations.   
Vitamin D supplementation activates GNMT in diabetic rats, but does not necessarily 
alter abundance.  Hepatic GNMT activity was induced in diabetic rats 1.3-fold, as compared 
to control rats (Figure 5.3A).  However, vitamin D supplementation in diabetic rats induced 
the activity of the enzyme above activity levels exhibited by rats treated with STZ alone (1.3-
fold) and 1.7-fold as compared to controls.  A diabetic state similarly induced GNMT protein 
abundance 3-fold and 4-fold in diabetic rats treated with vitamin D, as compared to the 
control group (Figure 5.3B).  However the difference in mean values between the diabetic 
groups did not reach significance (p = 0.1). 
SAM-dependent PEMT activity was increased in diabetic rats but vitamin D treatment 
was without effect.  Hepatic PEMT activity was elevated 1.5-fold in diabetic rats as compared 
to activity levels for control animals (Figure 5.4).  Vitamin D supplementation alone had no 
effect on PEMT activity.  However, in vitamin D-treated diabetic rats, PEMT activity was 
reduced to 80% of the activity level exhibited in STZ-treated rats alone.  Moreover, this 
value was not significantly different from the activity level in the control group, nor was it 
significantly different from the mean of the STZ-treated rats (p = 0.1). 
Remethylation did not restore plasma homocysteine concentrations in vitamin D-treated 
diabetic rats.  Differential enzyme activity induction was evident in STZ-treated rats (Table 
5.2).  Folate-independent hepatic BHMT activity increased 1.4-fold and 1.6-fold in diabetic 
and vitamin D-supplemented diabetic rats, respectively, as compared to the control group.  
Interestingly, vitamin D treatment alone effectively reduced BHMT activity 21%.  
Alternatively, STZ-treatment reduced the activity of the folate-dependent enzyme methionine 
synthase 73% and 86% in vitamin D supplemented diabetic rats as compared to the control 
animals.  Vitamin D treatment alone or in diabetic rats did not significantly alter hepatic MS 
activity. 
A diabetic state induced SAM-dependent global DNA hypomethylation, regardless of 
vitamin D treatment.  Both diabetic and vitamin D-supplemented diabetic rats exhibited a 
reduction in global DNA methylation 1.9- and 2.0-fold, respectively, as compared to control 
rats (Figure 5.5).  Vitamin D supplementation alone had no effect on methylation status.  
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Further, vitamin D supplementation in diabetic rats did not alter methylation status, as 
compared to diabetic rats. 
Homocysteine transsulfuration is not altered by vitamin D supplementation in diabetic 
rats.  A diabetic state induced catabolic transsulfuration of homocysteine (Figure 5.6).  
Abundance of the B6-dependent enzyme CBS, which initiates transsulfuration, was induced 
1.7-fold and 1.9-fold in diabetic and vitamin D-treated diabetic rats, respectively, as 
compared to control animals.  Similarly, plasma glutathione concentrations were elevated 
approximately 1.6-fold in STZ-induced diabetic rats compared to control rats.  However, 
vitamin D supplementation alone or in combination with STZ-treatment did not significantly 
alter homocysteine transsulfuration as compared to their respective controls. 
Discussion  
It has been well established that the interrelated homocysteine, folate, and methyl group 
metabolic pathways are critical in the prevention of a number of pathologies.  Thus it is 
paramount to understand the various factors that regulate these metabolic processes to 
promote optimal health.  We and others (101, 123, 198, 219, 220, 307) have shown that a 
chemically-induced type 1 diabetic state leads to the disruption of these interrelated pathways 
in hepatic tissue.  Specifically STZ-induced diabetic rats have reportedly altered 
transmethylation as evident by increased GNMT activity, mRNA, and protein abundance, 
PEMT activity and abundance, and hepatic DNA hypomethylation (101, 197, 198, 303).  
These animals also exhibited decreased folate-dependent remethylation and increased folate-
independent remethylation (198, 199, 220).  Furthermore, in diabetic rats with normal renal 
function, homocysteine transsulfuration is increased ultimately resulting in reduced plasma 
homocysteine concentrations (123, 198).  A number of studies indicate a diabetic state is also 
altered by vitamin D status.  Vitamin D deficiency has reportedly predisposed individuals 
and animals to both type 1 and 2 diabetes (173).  Impaired insulin secretion and glucose 
intolerance have also been reported in both humans and animals with vitamin D deficiency 
(37, 50, 202), but restoring vitamin D levels reverses these abnormalities (131).  Vitamin D 
supplementation in infants and in the genetically predisposed NOD mouse, has also been 
indicated in the reduction of type 1 diabetes development (7, 121, 175, 259).  Thus the goal 
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of this study was to determine if vitamin D supplementation impacts diabetes-perturbed 
methyl group metabolism. 
The most interesting finding in our study was the hypohomocysteinemia that resulted in 
diabetic animals and the restoration that followed calcitriol supplementation.  In this acute 
stage of diabetes without renal complications hypohomocysteinemia is commonly reported in 
both animals and humans with type 1 and 2 diabetes (123, 198, 224, 299).  However as renal 
complications ensue in chronic diabetes, hyperhomocysteinemia results in both type 1 and 2 
diabetics (118, 224), an independent risk factor for cardiovascular disease (132).    
Future studies should be conducted to determine the effect of vitamin D supplementation 
in chronic diabetic patients and animals with nephropathy.  In support of these findings, low 
serum concentrations of 1, 25-(OH)2D3 and its precursors are commonly reported in diabetics 
(10, 225, 243) which may result from increased urinary loss in diabetic nephropathy (204, 
273, 287).  Thus it is plausible that a diabetic state may be altering vitamin D metabolism; 
indicating diabetics may already have an increased requirement for vitamin D.  Further, 
epidemiological studies have indicated an association between low vitamin D status and an 
increased risk for metabolic syndrome, peripheral arterial disease, and ultimately 
cardiovascular disease (87, 157, 168, 184).  Thus, vitamin D may prove to be an important 
tool in lowering both homocysteine concentrations and the risk of cardiovascular disease in 
diabetics.   
Reduced homocysteine concentrations in diabetic rats is commonly the result of both 
increased transsulfuration and remethylation of the amino acid, as evident by increased CBS,  
γ-cystathionase, and both activity and mRNA levels of BHMT (123, 197, 219).  Our study 
also supported these findings.  In addition, we found elevated circulating glutathione 
concentrations in diabetic rats, again indicating increased catabolism of homocysteine in 
diabetic animals.  However, there were no significant changes in these enzymes in diabetic 
rats that received vitamin D supplementation, which does not explain the restored 
homocysteine concentrations.  Interestingly, vitamin D supplementation alone significantly 
decreased BHMT activity, although there has been no reports indicating a vitamin D-
response element in the promoter region for BHMT.  Similar to previous findings (197), 
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folate-dependent remethylation decreased in diabetic animals and was not altered 
significantly with vitamin D treatment.   
Altered transmethylation is also commonly reported in diabetic rats.  We report similar 
findings in diabetic animals, with increased GNMT activity and abundance, global DNA 
hypomethylation, and increased activity of PEMT.  However vitamin D supplementation 
increased GNMT activity further in diabetic rats, which may account for the return of 
homocysteine concentrations.  There was also a trend for the induction of GNMT protein 
level in vitamin D-supplemented diabetic rats over that which was exhibited in diabetic rats.  
Retinoic acid (RA), which acts similarly to 1, 25(OH)2D3 as a transcription factor, has also 
been reported to increase GNMT activity and abundance (231).  There are no reports 
however that GNMT contains a response element for either transcription factor.  Further, in 
previous studies RA alone was capable of inducing GNMT (198, 231).  Alternatively, 
vitamin D alone did not alter GNMT activity.  RA has also been reported to increase folate-
dependent remethylation through the activity of MS (208), but vitamin D treatment had no 
effect on MS activity.  Thus the two compounds may exert their effect through distinct 
mechanisms. 
Induction of GNMT would be expected to result in loss of methyl groups for additional 
transmethylation reactions.  DNA methylation status did support this assumption; however 
vitamin D supplementation did not induce any additional hypomethylation to mimic the 
induction of GNMT.  The DNA hypomethylation that resulted in diabetic rats was not 
significantly altered by vitamin D supplementation.  Although, it seems vitamin D 
supplementation may have restored PEMT activity, a primary user of SAM-derived methyl 
groups (126).  This trend however did not reach significance.   
Since blood glucose concentrations were not significantly altered in the vitamin D-treated 
diabetic animals, future studies need to focus on determining the ideal treatment period and 
dose.  It will also be ideal in future studies to examine the effect of vitamin D in diabetic 
patients and animals with nephropathy, possibly using a genetic model of diabetes, to further 
elucidate its effectiveness in restoring homocysteine concentrations.  Additionally, 
identifying the underlying mechanism for its action will also be vital in future studies.  Lack 
of insulin, excess counter-regulatory hormones to insulin, or elevated blood glucose may be 
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logical connections, since vitamin D depletion results in impairment of insulin secretion and 
insulin is a probable regulator of homocysteine metabolism. 
In summary, we have reported that type 1 diabetes disrupts homocysteine and methyl 
group metabolism and that vitamin D status may influence this disruption.  Since similar 
disruptions occur in type 2 diabetes (299) this may have future implications regarding 
vitamin D requirements in a diabetic state.  This may be especially significant for those with 
polymorphisms in proteins critical in both homocysteine and vitamin D metabolism, such as 
the vitamin D receptor and CBS.   
Footnotes 
1 Nieman KM2, Nieman MK3, Schalinske KL2.  Vitamin D supplementation maintains 
normal homocysteine metabolism in diabetic rats. FASEB J  21:226.2, 2007 (abstr.).  This 
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2 Graduate student and associate professor, Interdepartmental Graduate Program in 
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Tables 
 
 
 
 
 
Table 5.1 
Cumulative weight gain and blood glucose concentrations in rats treated with calcitriol 
(D) and/or streptozotocin (STZ)1 
1Values are means ± S.E. (n = 4-6).  Data in each column with distinct letters are 
significantly different (p ≤ 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 Cumulative Weight Gain (g) Blood glucose (mM) 
Control 137 ± 4a 9.9 ± 1.3a 
D 130 ± 5a 12.3 ± 1.3a 
STZ 90 ± 6b 26.6 ± 1.6b 
D+STZ 81 ± 7b 31 ± 0.1b 
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Table 5.2 
 
Hepatic activity of homocysteine remethylation enzymes, betaine-homocysteine S-
methyltransferase (BHMT) and methionine synthase (MS), in rats treated with streptozotocin 
(STZ) and calcitriol (D)1 
 
 
 
 
 
 
 
1Values are means ± SE (n = 4-6).  Distinct letters within each column indicate a 
significant difference (p ≤ 0.05). 
 
 
 
 
 
 
 
 
 BHMT    (units/mg protein) 
MS                 
(pmol/min•mg protein) 
Control 108 ± 4a 55 ± 6a 
D 85 ± 4b 47 ± 7a 
STZ 153 ± 13c 15 ± 2b 
D+STZ 174 ± 12c 8 ± 2b 
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Figure Legends 
 
Figure 5.1 
Homocysteine metabolism.  Homocysteine is synthesized from methionine, which is first 
activated to S-adenosylmethionine (SAM).  SAM, the primary methyl group donor provides 
methyl groups in a number of transmethylations reactions (X→X-CH3).  Following methyl 
group donation S-adenosylhomocysteine (SAH) is synthesized.  SAH is further hydrolyzed, 
forming homocysteine.  The abundant cytosolic protein, glycine N-methyltransferase 
(GNMT), optimizes the SAM:SAH ratio by utilizing methyl groups from SAM forming 
sarcosine and SAH from glycine.  Phosphatidylethanolamine N-methyltransferase (PEMT) is 
also a major consumer of SAM-dependent methyl groups in the synthesis of 
phosphatidylcholine (PC) from phosphatidylethanolamine (PE).  Homocysteine can either be 
remethylated to methionine or irreversibly catabolized through the transsulfuration pathway.  
Remethylation of homocysteine occurs through both folate- and betaine-dependent pathways.  
Folate-dependent remethylation occurs through the activity of the B12-dependent enzyme, 
methionine synthase (MS).  A methyl group is donated from 5-methyltetrahydrofolate (5-
CH3THF) resulting in tetrahydrofolate (THF) and methionine.  Homocysteine can also be 
remethylated with the donation of a methyl group from betaine, which is formed following 
the oxidation of choline.  Methionine and dimethylglycine (DMG) result through the activity 
of betaine-homocysteine S-methyltransferase (BHMT).  Alternatively homocysteine can be 
catabolized to cysteine which is initiated by the B6-dependent enzyme cystathionine β-
synthase (CBS).  Cysteine can then be used in the synthesis of glutathione. 
Figure 5.2 
Vitamin D supplementation maintains homocysteine concentrations in streptozotocin 
(STZ)-induced diabetic rats.  Rats were acclimated to their diet for 11 days.  The following 
day, the animals began an oral treatment regimen of 500 ng/kg body weight 1,25-
dihydroxyvitamin D3 (calcitriol, D) or the vehicle corn oil, every other day for the remainder 
of the study.  On day 21, the animals were given a single injection of streptozotocin (STZ, 60 
mg/kg body weight) or the vehicle 10 mM citrate buffer (pH 4.5).  Plasma samples were 
collected and total homocysteine concentrations were determined by HPLC and fluorometric 
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detection as described under “Materials and Methods.”  Data are expressed as means ± S.E. 
(n = 4-6) and bars labeled with distinct letters are significantly different (p ≤ 0.05). 
Figure 5.3 
Hepatic glycine N-methyltransferase (GNMT) induction in vitamin D-treated diabetic 
rats.  Liver samples were collected from the same animals as described for Figure 4.2 and 
GNMT activity and abundance were determined as described under the “Materials and 
Methods” section.  A: Hepatic GNMT activity in both diabetic and non-diabetic rats 
supplemented with vitamin D or the vehicle corn oil.  Data are expressed as means ± SE (n = 
4-6) and bars denoted with different letters are significantly different (p ≤ 0.05).  B: GNMT 
abundance was determined in the same animals as described above using Western blot 
analysis and a polycolonal GNMT antibody.  A representative immunoblot is pictured and 
the data are displayed in the graph.  Data are expressed as percent of the control ± S.E. (n = 
4-6) and bars labeled with different letters indicate a significant difference (p ≤ 0.05). 
Figure 5.4 
Induction of hepatic phosphatidylethanolamine N-methyltransferase (PEMT) in 
streptozotocin (STZ)-induced diabetic rats may be prevented by vitamin D supplementation.  
Microsomal fractions of liver were collected to determine PEMT activity from the animals as 
described for Figure 4.2.  PEMT activity was assessed as described under the “Material and 
Methods” section in both diabetic (STZ) and non-diabetic animals treated with supplemental 
vitamin D (calcitriol, D), or the vehicle.  Data are expressed as means ± S.E. (n = 4-6) and 
bars denoting distinct letters are significantly different (p ≤ 0.05). 
Figure 5.5 
Global DNA hypomethylation in streptozotocin (STZ)-induced diabetic rats.  Liver was 
collected for DNA isolation from both diabetic (STZ) and non-diabetic animals treated with 
supplemental vitamin D or the vehicle corn oil, which are the same animals as described for 
Figure 4.2.  Global methylation status was determined using [3H]-dCTP, where incorporation 
of radiolabeled dCTP is directly proportional to unmethylated sites as described in the 
“Materials and Methods” section.  These data are expressed as means ± S.E. (n = 4-6) and 
bars displaying distinct letters indicate a significant difference (p ≤ 0.05). 
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Figure 5.6 
Homocysteine transsulfuration is not altered in streptozotocin (STZ)-induced diabetic rats 
treated with supplemental vitamin D (calcitriol, D), as evident by hepatic cystathionine β-
synthase (CBS) abundance and plasma glutathione concentrations.  Liver and plasma 
samples were collected from the same animals as described for Figure 4.2.  CBS abundance 
was assessed by Western blot analysis using a polyclonal CBS antibody and displayed in a 
representative blot.  Glutathione concentrations were determined using HPLC with 
fluorometric detection.  Both analyses are described under the “Material and Methods” 
section.  Data are expressed as means ± S.E. (n = 4-6) and displayed as a percent of the 
control group mean.  Bars denoted with different letters are significantly different (p ≤ 0.05). 
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Figure 5.2 
 
 
 
 
0
4
8
12
16
20
T
ot
al
 P
la
sm
a 
H
om
oc
ys
te
in
e 
(μ
M
)
a 
a 
b 
a 
Control D STZ D+STZ 
 99 
 
Figure 5.3A 
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Figure 5.3B 
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Figure 5.4 
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Figure 5.5 
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CHPATER 6: GENERAL CONCLUSIONS 
Folate, homocysteine, and methyl group metabolism function in concert to provide 
activated one-carbon units in the modification and synthesis of essential biological 
compounds.  Therefore, interruptions in these vital pathways may have adverse implications 
in health and disease.  This document further elucidates modifications in methyl group 
metabolism in a streptozotocin-induced diabetic state, characterized by reduced circulating 
insulin and elevated counter-regulatory hormones to insulin, essentially a gluconeogenic 
state.  In addition we have investigated several different means (i.e. folate, vitamin D, and 
insulin administration) of preventing perturbation of homocysteine and methyl group 
metabolism in a diabetic state.  
Following insulin administration, the elevation in GNMT activity and 
hypohomocysteinemia in diabetic rats was completely prevented by insulin treatment. 
Additionally, disruptions in methionine synthase (MS), PEMT, and DNA methylation were 
also prevented by insulin injections.  Similar findings have been reported in a type 2 diabetic 
model, therefore it is suspected that glucose or insulin levels may represent a regulatory 
signal to modify GNMT and homocysteine.  Moreover, this study suggests perturbations in 
folate, homocysteine, and methyl group metabolism result from a diabetic state as opposed to 
complications of streptozotocin toxicity. 
The activities of GNMT, phosphatidylethanolamine N-methyltransferase (PEMT), and 
betaine-homocysteine S-methyltransferase (BHMT) were increased approximately 2-fold in 
the diabetic rat liver; folate deficiency resulted in the greatest elevation in GNMT activity. 
This elevation is likely due to a lack of folate which would otherwise impose 
posttranslational inhibition of GNMT.  Although these results would suggest that adequate 
folate status has a positive effect under diabetic conditions, supplemental folate did not 
confer any added benefit at the level tested.  However this does stress the importance of 
adequate folate, especially in diabetics.  The abundance of GNMT protein and mRNA, as 
well as BHMT mRNA, were also elevated in diabetic rats.  Thus perturbation of 
homocysteine and methyl group metabolism in a diabetic state is likely at the level of 
transcription.  Hyperhomocysteinemia in folate-deficient rats was attenuated by 
streptozotocin, probably owing in part to increased BHMT expression.  These results indicate 
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that a diabetic state profoundly modulates methyl group, choline, and homocysteine 
metabolism, and folate status may play a role in the extent of these alterations.   
Vitamin D supplementation prevented hypohomocysteinemia in diabetic rats, which is 
likely due to an induction of GNMT.  It did not prevent other diabetes-mediated alterations in 
homocysteine remethylation or transsulfuration.  Taken together, it appears that vitamin D 
supplementation may be beneficial by maintaining normal homocysteine metabolism 
disrupted by a diabetic state. 
Approximately seven percent of the American people are affected by diabetes.  The 
results reported in this document may have significant implications for complications 
associated with this devastating disease.  Many questions remain and need to be addressed by 
future research.  First, it will be important to determine if a greater reduction in GNMT 
activity can be achieved with higher doses of folate, a different route of supplementation, 
and/or longer treatment times.  Secondly, it will also be necessary to determine the 
mechanism of action of vitamin D.  Insufficient vitamin D levels are often reported in 
diabetic humans, so it will be critical to determine the proper treatment regimen.  In the work 
described here and in combination with other studies, it seems that a lack of insulin, 
increased glucose, or increased circulating counter-regulatory hormones to insulin may be a 
signal for regulating homocysteine and methyl group metabolism.  This regulation likely 
occurs at the level of transcription since BHMT, CBS, and GNMT mRNA abundance have 
all been reportedly increased in type 1 diabetic rats.  BHMT and CBS mRNA are also 
elevated in a type 2 diabetic rat model.  However there are currently no reports in the 
literature of glucocorticoid-response elements in these genes.  Thus it is plausible that the 
regulatory mechanism involves an intermediate or the regulation is at the level of mRNA 
stability.  It will also be critical to determine the efficacy of the regulatory strategies 
presented, in genetic models of type 1 and type 2 diabetes, as opposed to the chemically-
induced model used in these studies.  Moreover, the evidence presented here indicates 
diabetics may have an increased requirement for nutrients such as choline, folate, other B 
vitamins involved in one-carbon metabolism (e.g. B12 and B6), and possibly vitamin D.  This 
will be particularly important in diabetics that express polymorphisms in the enzymes 
involved. 
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